ACTIV -6: COVID -19 Study of Repurposed Medications - Arm B (Fluvoxamine)   
[STUDY_ID_REMOVED]  
Protocol [v3.0] date Jul 06, 2021  
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 1  
 
 
ACTIV -6: COVID -19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed 
Medications  
 
 
 
 
Protocol Number:  
 Pending  
PIND Number:  
 155481  
Principal Investigator:  Adrian Hernandez, MD, MHS  
Duke Clinical Research Institute  
200 Morris St.  
Durham, NC 27701  
Phone: 919 -668-7515 
Email: adrian.hernandez@duke.edu  
Co-Principal 
Investigator /IND 
Sponsor : Susanna Naggie, MD, MHS  
Duke Clinical Research Institute  
200 Morris St.  
Durham,  NC 27701  
Phone: 919 -684-2584 
Email: susanna.naggie@duke.edu  
Data Coordinating 
Center Investigator  Chris Lindsell , PhD 
Vanderbilt University School of Medicine  
2525 West End Avenue  
Suite 1100, Rm 11129  
Nashville , TN 37203  
Phone: 615-343-9867 
Email: chris.lindsell@vumc.org  
Lead   
Funding Agency:  
 National Center for Advancing Translational Sciences  
Version:  
 3.0 
Date:  06JUL 2021 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 2 Statement of Compliance  
 
This trial will be conducted in compliance with the International Council for Harmonisation 
(ICH) E6 (R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory 
requirements from the United States (US) Code of Federal Regulations (CFR), including 45 CFR 
46 (Human Subjects Protection); 21 CFR 312 (Investigational New Drug); 21 CFR 50  (Informed 
Consent), and 21 CFR 56 (Institutional Review Board).  
All individuals who are responsible for the conduct, management, or oversight of this study ha ve 
completed Human Subjects Protection and ICH GCP Training.  
 
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 3 Site Principal Investigator Statement  
 
I have read the protocol, including all appendices, and the package insert (s)/product label (s), and 
I agree that the protocol contains all necessary details for my staff and me to conduct this study 
as described. I will personally oversee the conduct of this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. I agree to make all 
reasonable effort s to adhere to the attached protocol.  
I will provide all study personnel under my supervision with copies of the protocol and access to 
all information provided by the sponsor or the sponsor‚Äôs representative.  I will discuss this 
material with study personn el to ensure that they are fully informed about the efficacy and safety 
parameters and the conduct of the study in general. I am aware that, before beginning this study, 
the IRB, or equivalent oversite entity must approve this protocol in the clinical faci lity where it 
will be conducted.  
I agree to obtain informed consent from participants, as required by the IRB of record  and 
according to government regulations and I CH guidelines. I further agree to report to the sponsor 
or its representative any adverse e vents in accordance with the t erms of this protocol and the U S 
CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in 
accordance with the provisions as stated and will comply with the prevailing local laws and 
customs . 
 
 
   
Site Principal Investigator Name (Print)   
   
   
Site Principal Investigator Signature   Date  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 4 Table of Contents  
1. Protocol Summary ................................ ................................ ................................ . 12 
1.1. Synopsis  ................................ ................................ ................................ ..................  12 
1.2. Schema  ................................ ................................ ................................ ....................  18 
2. Introduction  ................................ ................................ ................................ ..........  19 
2.1. Study Rationale  ................................ ................................ ................................ ........  19 
2.2. Background ................................ ................................ ................................ ..............  19 
2.3. Benefit/Risk Assessment  ................................ ................................ ..........................  20 
2.3.1.  Risk Assessment ................................ ................................ ................................ ....... 20 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ .. 20 
3. Objectives and Endpoints ................................ ................................ ......................  21 
4. Study Design ................................ ................................ ................................ ..........  23 
4.1. Overall Design  ................................ ................................ ................................ .........  23 
4.2. End of Study Definition ................................ ................................ ............................  23 
5. Study Population  ................................ ................................ ................................ ... 24 
5.1. Inclusion Criteria ................................ ................................ ................................ ...... 24 
5.2. Exclu sion Criteria  ................................ ................................ ................................ .... 24 
5.3. Recruitment and Engagement  ................................ ................................ ...................  24 
5.3.1.  Participant Recruitment  ................................ ................................ ............................  24 
5.3.2.  Participant Engagement  ................................ ................................ ............................  24 
5.3.3. Participant Randomization Process ................................ ................................ ............  25 
5.4. Screen Failures ................................ ................................ ................................ .........  25 
5.5. Enrollment  ................................ ................................ ................................ ...............  25 
6. Study Drug(s)  ................................ ................................ ................................ ........  26 
6.1. Repurposed Medication Treatments  ................................ ................................ ..........  26 
6.2. Placebo  ................................ ................................ ................................ ....................  26 
6.3. Study Drug Accountability  ................................ ................................ .......................  26 
6.4. Concomitant Therapy  ................................ ................................ ...............................  26 
6.5. Intervention After the End of the Study  ................................ ................................ ..... 26 
7. Participant Withdrawal/Termination and Study Termination .............................  27 
7.1. Participant Withdrawal/Termination  ................................ ................................ .........  27 
7.2. Premature Termination or Suspension of the Study ................................ ....................  27 
7.3. Lost to Follow -up ................................ ................................ ................................ ..... 27 
8. Study A ssessments and Procedures ................................ ................................ ....... 29 
8.1. Schedule of Events  ................................ ................................ ................................ ... 30 
8.1.1.  Screening  ................................ ................................ ................................ .................  31 
8.1.2.  Intervention Period  ................................ ................................ ................................ ... 31 
8.1.3.  Follow -up Period  ................................ ................................ ................................ ...... 32 
8.1.4.  Final Visit  ................................ ................................ ................................ ................  32 
8.2. Clinical Assessments  ................................ ................................ ................................  33 
8.3. Quality of Life Questionnaires  ................................ ................................ ..................  34 
9. Safety Assessments  ................................ ................................ ................................  35 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 5 9.1. Adverse  Events and Serious Adverse Events  ................................ .............................  35 
9.1.1.  Adverse Device Effect (ADE) and Unanticipated Adverse 
Device Effect (UADE) ................................ ................................ ..............................  35 
9.1.2.  Collection Period for AE and SAE Information  ................................ .........................  36 
9.1.3.  Assessing Causality of a Serious Adverse Event  ................................ ........................  37 
9.1.4.  Reporting and Monitoring of SAEs  ................................ ................................ ...........  37 
9.1.5.  Events of Special Interest ................................ ................................ ..........................  38 
9.2. Unanticipated Problem (UP) and Terminations ................................ ..........................  39 
9.2.1.  Definition of Unanticipated Problem  ................................ ................................ .........  39 
9.2.2.  Reporting of an Unanticipated Problem  ................................ ................................ ..... 39 
10. Statistical Considerations  ................................ ................................ ......................  40 
10.1.  Statistical Hypotheses ................................ ................................ ...............................  40 
10.1.1.  Primary Hypothesis  ................................ ................................ ................................ .. 40 
10.2.  Sample Size Determination ................................ ................................ .......................  40 
10.3. Randomization  ................................ ................................ ................................ .........  40 
10.4.  Blinding ................................ ................................ ................................ ...................  40 
10.5.  Populations for Analyses  ................................ ................................ ..........................  41 
10.6.  Statistical Analyses  ................................ ................................ ................................ .. 41 
10.6.1.  General Considerations  ................................ ................................ .............................  41 
10.6.2.  Statistical modeling  ................................ ................................ ................................ .. 42 
10.6.3. Model priors ................................ ................................ ................................ .............  43 
10.6.4.  Assessing Effectiveness  ................................ ................................ ............................  44 
10.6.5.  Planned Interim Analyses, Early Stopping, and Type -I Error 
Control ................................ ................................ ................................ .....................  44 
10.6.6.  Sensitivity and Supplementary Analyses  ................................ ................................ ... 45 
10.6.7.  Differential Treatment Effects and Subgroup Analyses  ................................ ..............  46 
10.6.8.  Secondary Clinical Endpoint  ................................ ................................ .....................  46 
10.6.9.  Exploratory Analysis  ................................ ................................ ................................  46 
10.6.10.  Adherence and Retention Analysis  ................................ ................................ ............  47 
10.7.  Interim Reporting  ................................ ................................ ................................ ..... 47 
10.8.  Independent Data Monitoring Committee (IDMC)  ................................ ....................  47 
10.9.  Adjudication Committee ................................ ................................ ...........................  48 
11. Ethical Standards  ................................ ................................ ................................ .. 49 
11.1.  Institutional Review Board (IRB) ................................ ................................ ..............  49 
11.2.  Informed Consent Process  ................................ ................................ ........................  49 
11.3.  Participant and Data Confidentiality ................................ ................................ ..........  49 
11.4.  Site Management and Quality Assurance  ................................ ................................ .. 50 
11.5.  Site Monitoring  ................................ ................................ ................................ ........  50 
12. Data Handling and Record Keeping  ................................ ................................ ..... 51 
12.1.  Data Collection and Management Responsibilities  ................................ ....................  51 
12.2.  Study Records Retent ion ................................ ................................ ..........................  51 
12.3.  Protocol Deviations  ................................ ................................ ................................ .. 51 
12.4.  Publication and Data Sharing Policy  ................................ ................................ .........  51 
13. Study Leadership  ................................ ................................ ................................ .. 53 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 6 14. Summary of Changes  ................................ ................................ ............................  54 
15. References  ................................ ................................ ................................ .............  56 
16. Appendix A ‚Äì Ivermectin  ................................ ................................ ......................  61 
16.1.  Risk Assessment  ................................ ................................ ................................ ...... 61 
16.2.  Additional Appendix -Level Exclusion Criteria  ................................ ..........................  62 
16.2.1.  Precautions ................................ ................................ ................................ ...............  62 
16.3.  Ivermectin Information  ................................ ................................ .............................  63 
16.3.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  63 
16.3.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 63 
16.3.3.  Dosing and Administration  ................................ ................................ .......................  63 
16.3.4.  Rationale for Selection of Dose  ................................ ................................ .................  63 
16.4.  Placebo Information  ................................ ................................ ................................ . 65 
16.4.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  65 
16.4.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 65 
16.4.3.  Dosing and Administration  ................................ ................................ .......................  65 
16.5.  Events of Special Interest  ................................ ................................ .........................  65 
17. Appendix B ‚Äì Fluvoxamine Maleate  ................................ ................................ ..... 66 
17.1.  Risk Assessment  ................................ ................................ ................................ ...... 66 
17.2.  Additi onal Appendix -Level Exclusion Criteria  ................................ ..........................  67 
17.2.1.  Precautions ................................ ................................ ................................ ...............  68 
17.3.  Fluvoxamine Information  ................................ ................................ .........................  68 
17.3.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  68 
17.3.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 69 
17.3.3.  Dosing and Administration  ................................ ................................ .......................  69 
17.3.4.  Rationale for Selection of Dose  ................................ ................................ .................  69 
17.4.  Placebo Information  ................................ ................................ ................................ . 72 
17.4.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  72 
17.4.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 72 
17.4.3.  Dosing and Administration  ................................ ................................ .......................  72 
17.5.  Events of Special Interest  ................................ ................................ .........................  72 
18. Appendix C ‚ÄìFluticasone Furoate  ................................ ................................ .........  73 
18.1.  Risk Assessment  ................................ ................................ ................................ ...... 73 
18.2.  Additi onal Appendix -Level Exclusion Criteria  ................................ ..........................  74 
18.2.1.  Precautions ................................ ................................ ................................ ...............  74 
18.3.  Fluticasone Furoate Information  ................................ ................................ ...............  75 
18.3.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  75 
18.3.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 75 
18.3.3.  Dosing and Administration  ................................ ................................ .......................  75 
18.3.4.  Rationale for Selection of Dose  ................................ ................................ .................  75 
18.4.  Placebo Information  ................................ ................................ ................................ . 76 
18.4.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................  76 
18.4.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ .... 77 
18.4.3.  Dosing and Administration  ................................ ................................ .......................  77 
18.5.  Events of Special Interest  ................................ ................................ .........................  77 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 7 18.6.  Safety Reporting for Fluticasone Furoate  ................................ ................................ .. 77 
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 8 Abbreviations  
ACE  Angiotensin -converting Enzyme  
ADE  Adverse Device Effect  
AE Adverse Event  
ARB  Angiotensin II Receptor Blockers  
ARNI  Angiotensin Receptor Neprilysin Inhibitor  
BiPAP  Bilevel Positive Airway Pressure  
BMD  Bone Mineral Density  
BMI Body Mass Index  
CCC  Clinical Coordinating Center  
CEA  Clinical Event Ascertainment  
CFR Code of Federal Regulations  
CONSORT  Consolidated Standards of Reporting Trials  
COPD  Chronic Obstructive Pulmonary Disease  
COVID -19 Coronavirus Disease 2019  
CPAP  Continuous Positive Airway Pressure  
DCC  Data Coordinating Center  
DIC Disseminated Intravascular Coagulation  
DUA  Data Use Agreement  
ECMO  Extracorporeal Membrane Oxygenation  
EDC  Electronic Data Capture  
ESI Event of Special Interest  
FDA  Food and  Drug Administration  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus 
IC50 Half-Maximal Inhibitory C oncentration  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICS Inhaled Corticosteroid  
ICU Intensive Care Unit  
IDMC   
IDS Investigational Drug Service  
IRB Institutional Review Board  
KO Knockout  
LPS Lipopolysaccharide  
MAOI  Monoamine Oxidase Inhibitors  
mITT  Modified Intention to Treat  
MOP  Manual of Procedures  
NCATS  National Center for Advancing Translational Sciences  
NIH National Institute  of Health  
OCD  Obsessive Compulsive Disorder  
OHRP  Office for Human Research Protections  
OR Odds Ratio  
PCORI  Patient -Centered Outcomes Research Institute  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 9 PCR  Polymerase Chain Reaction  
PHI Personal Health Information  
PHQ  Patient Health Questionnaire  
PPOS  Predicted Probability of S uccess  
PROMIS  Patient -reported Outcomes Measurement Information System  
QOL Quality of Life  
RRT  Renal Replacement Therapy  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV-1/2 Severe Acute Respiratory S yndrome Coronavirus 1/2 
SD Standard Deviation  
SNRI  Selective Norepinephrine Reuptake Inhibitor  
SSRI  Selective Serotonin  Norepinephrine Reuptake Inhibitor  
SUSAR  Serious Unexpected Suspected Adverse Reaction  
UADE  Unanticipated Adverse Device Effect  
UP Unanticipated Problems  
US United States  
WT Wildtype  
  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 10 Table of Figures  
Figure 1: ACTIV -6 Study Schema  ................................ ................................ .......................... 18 
Figure 2: Operational Structure Diagram  ................................ ................................ ................. 53 
Figure 3: Survival curve of WT and S1R KO mice  ................................ ................................ ..70 
Figure 4:  Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early COVID -
19. ................................ ................................ ................................ ................................ ......... 71 
Figure 5:  Summary of study  results for the prospective, nonrandomized observational cohort 
study with fluvoxamine in participants diagnosed with COVID -19................................. .......... 71 
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 11 List of Tables  
Table 1: Schedule of Events  ................................ ................................ ................................ ....30 
Table 2: ACTIV -6 Sample Size Estimates and Power  ................................ .............................. 40 
Table 3: Ivermectin Adverse Event Table for Doses ‚â• 300 ¬µg/kg ................................ ............. 61 
Table 4: Ivermectin Dosing Schedule  ................................ ................................ ...................... 63 
Table 5. Fluvoxamine Adverse events occurring in 10 -week studies of adult OCD or depression
 ................................ ................................ ................................ ................................ .............. 66 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants receiving 
300 mg/day for 15 days. ................................ ................................ ................................ .......... 67 
Table 7. Fluticasone Adverse reactions that occurr ed in ‚â•3% of adults and adolescents with 
asthma in a 24 -week trial.  ................................ ................................ ................................ .......73 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 12 1. Protocol Summary  
1.1. Synopsis  
 
Title ACTIV -6: COVID -19 Outpatient Randomized Trial to Evaluate 
Efficacy of Repurposed Medications  
Clinical study phase  III 
Rationale  Coronavirus Disease 2019 ( COVID -19) is caused by a novel 
coronavirus, severe acute respiratory syndrome coronavirus 2 
(SARS -CoV-2), that first emerge d in December  2019 and has since 
resulted in  a global pandemic unseen in almost a century  in cases 
and mortality. Over 2020, advances were made for treatment of 
COVID -19 and several vaccinations for prevention of SARS -CoV-
2 infection  have received emergency use authorizatio n. However, 
the pandemic continues to evolve with new variants and surges of 
infections in different regions of the world , requiri ng an ongoing 
evidence -generating  clinical trial  platform, in particular for the 
treatment of COVID -19 in the outpatient setti ng. This platform 
protocol can serve as an evidence generation system for prioritized 
drugs , repurposed from other  Food and Drug Administration ( FDA ) 
indications with an established safety record  in humans  and 
preliminary data of efficacy.  The ultimate goa l is to evaluate if 
repurposed medications can make p articipants fee l better faster and 
reduce death and hospitalization.  
Primary Objective  ÔÇ∑ To evaluate the effectiveness  of repurposed  medications  [(study 
drug(s)]  in reducing symptoms of nonhospitalized participants 
with mild to moderate  COVID -19 
Secondary 
Objectives  ÔÇ∑ To evaluate the clinical outcomes  (e.g. hospitalization and 
death) in participants in a study drug  arm versus those in the 
placebo arm  
ÔÇ∑ To describe symptom resolution  in participants in a study drug 
arm versus those in the placebo arm  
ÔÇ∑ To describe the quality of life (QOL) in participants in a study 
drug arm versus those in the placebo arm  
Exploratory 
Objectives  ÔÇ∑ To describe long -term COVID -19-related symptoms in 
participants in a study drug  arm versus those in the placebo 
arm  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 13 Intervention  All interventions will occur in addition to standard of care. Each 
study drug appendix describes a different study drug and 
matching placebo. The following arms will be included in each 
study  appendix : 
ÔÇ∑ Study Drug  Arm: repurposed medications (see 
Appendices)  
ÔÇ∑ Placebo  Arm: placebo  control  
While each appendix describes  the placebo that matches the 
study drug, for comparative analysis the control group will 
comprise  eligible , concurrent ly enrolled participants from all 
placebo arms .  
Study Design  This study is a platform  protocol designed to be flexible so that 
it is suitable for a wide range of settings within healthcare 
systems and in community settings where it can be integrated 
into routine COV ID-19 testing programs and subsequent 
treatment plans. Th is platform  protocol will enroll participants in 
an outpatient setting with a confirmed polymerase chain reaction 
(PCR ) or antigen test for SARS -CoV-2. Each appendix will 
describe a repurposed medica tion ( study drug ) to meet the 
protocol objectives.  
When only one study drug/appendix  is under study, allocation 
between study drug and placebo will be 1:1. If multiple study 
drugs/appendices  are under study, participants will  also be 
randomized among the study drugs  for which eligibility is 
confirmed. Since the route of administration of each study drug 
may differ, the placebos may also differ. To achieve blinding 
and an equitable randomization probability, a  two step 
randomization process will be used . 
In the first step, the participant will be  randomized m:1 active  
study drug  to placebo, where m is the number of active study 
drugs  for which the participant is eligible.  Then, participants  will 
be randomized among the  m study drugs  for which they are 
eligib le. Participants wi ll carry their ‚Äò study drug ‚Äô versus 
‚Äòplacebo‚Äô randomization with them into the study drug appendix . 
In this way, a participant  allocated to placebo who is randomized 
to study drug A will be given the placebo that matches study 
drug A. This achieves equal probability of exposure to a placebo 
or an active  study drug , and equitable distribution among all 
study arms for which a participant is eligible.  Sites will be 
informed to which study drug appendix  the participant is  
randomized , but not whether they are allocated to the study drug  
arm or placebo  arm within that appendix .  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 14 For analysis, concurrent placebo participants who were eligible 
for the study  drug appendix  will be pooled. This will result in 
approximately a 1:1 allocation ratio for any study drug to 
placebo.  If a study drug appendix  is stopped for efficacy and 
becomes standard of care, the active study drug  arm may serve 
as a concurrent placebo for other st udy drugs.   
Participants will receive complete supply of repurposed 
medication (study drug) or placebo  with length of treatment and 
amount of study drug/placebo  depending on the  study drug 
appendix and arm  to which  they are randomize d. 
This study is designed so that it can be done completely 
remote ly. However, screening and enrollment may occur in 
person at sites and unplanned s tudy visit s may occur in -person  
or remotely , as deemed appropriate by an investigator  for safety 
purposes . Participants will be on -study for 90 days, during which 
they will complete various questionnaires.  
Population  Up to 15,000  adults   
Study Duration  24 months  
Study Location  Up to 280 sites   
Inclusion Criteria  1. Completed Informed Consent  
2. Age ‚â•30 years old  
3. Confirmed SARS -CoV-2 infection by any authorized  or 
approved PCR or antigen  test collected within 10 days of 
screening  
4. Two or more c urrent symptoms of acute infection for ‚â§ 7 days. 
Symptoms include the following:  fatigue, dyspnea, fever, cough, 
nausea, vomi ting, diarrhea, body aches , chills, headache, sore 
throat, nasal symptoms, new loss of sense of taste or smell  
Exclusion Criteria  1. Prior diagnosis of COVID -19 infection  (> 10 days from 
screening)  
2. Current or recent (within 10 days of screening) h ospitalization  
3. Current use of study drug or study drug/device combination*   
4. Known allergy/sensitivity or any hypersensitivity to 
compone nts of the study drug or placebo * 
5. Known contraindication to study drug  including prohibited 
concomitant medications (see Appendices) * 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 15 *If only one study drug  appendix  is open at the time of enrollment. 
If multiple study drug appendices  are open, a participant may opt -
out of any study drug  appendix or be excluded from any study drug  
appendix based  on contraindications listed in the study drug 
appendix , current use of study drug,  or known 
allergy/sensitivity/hypersensitivity  and still remain eligible for the 
remaining study drug appendi ces. 
Sample S ize 
Considerations  An estimated sample size of ~ 600 participants per study drug 
appendix  is needed to have >85% power to determine whether 
there is evidence of meaningful benefit . This will involve 300 
participants in the active study drug  arm and 300 concurrent 
placebo controls. Moreover, when a  study drug  demonstrates 
overall effectiveness, the planned adaptations to increase accrual 
up to 1 200 participants  (600 receiving the active study drug  and 
600 receiving the placebo)  for the purpose of demonstrating 
benefit on clinical events is a reasonable extension within the 
context of this platform. This study will enroll up to 15,000 
adults, depending on the number of study drug  appendice s that 
are added and adjustments to sample size depending on the data.  
General Statistical 
Consideration for 
Primary Analysis  The primary outcome of interest for this platform is symptom s, 
collected  using a web-assisted symptom d iary according to Table 1. 
Symptoms will be counted  on an ordinal scale.  
The overall effect of each study drug versus matching placebo will 
be quantified using the common odds ratio ( OR) from the 
proportional odds model (primary estimand). Evidence for efficacy 
will be quantified as the posterior probability that the OR is less 
than 0.9. This is denoted as the ‚Äúposterior probability for efficacy‚Äù 
or ùëÉ(ùëÇùëÖ<0.9|Data ). Similarly, the risk difference in 
hospitalization or d eath will be used to draw conclusions about 
clinical efficacy. Regardless of whether there is an efficacy signal, 
the following quantities from the model  will be reported : 
ÔÇ∑ Mean and median time to symptom resolution  (for quantifying 
benefit on symptoms)  
ÔÇ∑ Mean and median time to hospitalization or death (secondary 
outcomes)  
The primary analysis will be implemented separately for each study 
drug, where the matching placebo arm will consist of concurrently 
randomized participants that meet the inclusion and excl usion 
criteria for that study drug  appendix . A modified intention to treat  
(mITT) approach will be used for primary analyses ; all participant s 
who receive study drug will be included as assigned . It is possible  
that the delivery of medications (placebo or study drug ) does not 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 16 occur; this will result in exclusion of the participant for the mITT 
analysis. All available data will be used to compare each study drug 
versus placebo control, regardless of post -randomization  adherence 
to study protocols.  
Independ ent Data 
Monitoring 
Committee (IDMC )  Frequent IDMC  reviews will be conducted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by 
treatment group. Regular IDMC  meetings will monitor the 
following parameters at a minimu m: 
ÔÇ∑ Recruitment progress  
ÔÇ∑ Enrollment overall and by subgroups  
ÔÇ∑ Adherence, retention, and status of data collection  
ÔÇ∑ Serious adverse events  
ÔÇ∑ Assessment for futility  
ÔÇ∑ Probability for benefit across endpoints  
Interim Analysis  Interim analyses will be performed per s tudy drug appendix , after 
approximately every 200 participants  (100 in study drug arm and 
100 in placebo arm)  have completed the Day  14 Visit. Placebo 
control participants contributing to this count will be drawn from 
across study drug appendices , and  will include participants who  
were eligible for the study drug appendix  of interest regardless of 
final study d rug arm allocation . The following decision thresholds 
will be checked at each interim  analysis : 
i) The study d rug is found to have benefit (efficacy) : A 
posterior probability of meaningful benefit  (e.g. OR < 
0.9) for a  study drug in comparison to the placebo 
control of > 0.95 will result in a declaration of  overall  
superiority.   
a. If a study drug arm is declared superior, a futility 
analysis will be conducted on observing clinical 
efficacy (reduction in hospitalizations or death) if the 
study drug arm were to continue for an additional 
one year . Accrual will be projected based on actual 
trial accrua l and projected case rates. Stopping for 
futility will be strongly encouraged if the predicted 
probability of success (PPOS) is  low (e.g.  <0.1) and 
will be discouraged if the PPOS is  high (e.g.  >0.7).   
ii) The study d rug is found to be substantially similar t o the 
placebo control  (inefficacy ): A posterior probability of 
>0.95 that there is  no more than trivial benefit (e.g. OR 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 17 > 0.9) or harm of an arm will result in termination of 
that arm.   
iii) The study d rug is found to cause harm (inferiority) : A 
posterior probability of >0.85 for worse adverse clinical 
outcomes (hospitalization or death) for a  study drug 
relative to the p lacebo control  (e.g. a risk difference  > 
0.01) will result in termination of that arm.  
iv) The predicted probability of success of any study drug 
given expected accrual at a prespecified point in time 
will be provided to the IDMC . Stopping for futility will 
be strongly encouraged if the PPOS is low (e.g. <0. 1) 
and will be discouraged if the PPOS is high (e.g. >0.7).  
Note that unli ke the probability of inefficacy, PPOS 
involves Bayesian posterior predictive distributions.  
Futility is a low probability of achieving any conclusions within a 
reasonable time frame or with available resources . Prior to each 
interim analysis, the target d ate for study completion will be 
specified, and accrual will be projected by that target date. A 
statistical model may be used to predict accrual.  Futility assessment 
will use the lowest of either the planned accrual or predicted 
accrual at study closure.  
The combination of decision thresholds and effect sizes have been 
selected to balance the ability to observe a meaningful effect on 
symptoms, to observe the potential for an effect on clinical 
outcomes, and to maximize power. In making decisions, power wil l 
be balanced with the  Type 1 error rate. For each study drug, 
simulations will be used to demonstrate that the operating 
characteristics are consistent with a Type I error control of at least 
5%. 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 18 1.2. Schema  
 
 
Figure 1: ACTIV -6 Study Schema  

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 19 2. Introduction  
2.1. Study Rationale  
Severe acute respiratory syndrome coronavirus 2  (SARS -CoV-2) is a novel betacoronavirus  that 
first emerged in December 2019  and has since caused a global pandemic unseen in almost a 
century  with respect to the number of cases and overall mortality. [1, 2]  The clinical disease 
related to  SARS -CoV-2 is referred to as Coronavirus Disease 2019 ( COVID -19). Over 2020, 
advances were made for treatment of COVID -19 and several vaccinations have received 
emergency use authorization for prevention of SARS -CoV-2 infections.  [3-8] However, the 
pandemic continues to evolve with new variants and surges of infections in different regions of 
the world , requiring an ongoing evidence -generating  platform, in particular for the  treatment of 
COVID -19 infection in the outpatient setting. This platform protocol can serve as an evidence 
generatin g system for prioritized drugs repurposed from other indications with an established 
safety record and preliminary evidence of clinical effi cacy for the treatment of COVID -19. The 
ultimate goal is to evaluate if repurposed medications can make participants feel better faster and 
reduce death and hospitalization.  
2.2. Background  
In December  2019,  numerous patients in Wuhan, China were diagnosed with  pneumonia caused 
by an unknown virus. By January 7, 2020,  Chinese scientists had isolated SARS -CoV-2. This is 
a novel betacoronavirus closely related to severe acute respiratory syndrome coronavirus  1 
(SARS -CoV-1). [2]  In the subsequent months the spread of the virus led to  a global pandemic. 
As of February 10 , 2021 there were approximately  107,002,486  confirmed  COVID -19 cases 
resulting in  2,343,477  deaths worldwide. [1] 
The virus continues to spre ad despite social distancing measures and travel restrictions. COVID -
19 vaccinations are actively being distributed  and administered  in some countries ; however, new 
SARS -CoV-2 strains continue to emerge, with early reports of potential for  reduced  monoclon al 
antibody therapeutic and  vaccine efficacy.  [9] Additionally, data regarding transmission  after 
vaccination is pending , highlighting the need to establish treatment regimens despite vaccination 
availability. Finally, while vaccine roll -out is occurring, sufficient  immune  coverage to reach 
herd immunity across the globe is unlikely in the next year. Thus, there remains a need to 
identify safe and efficacious  treatments that can be administered in the outpatient setting.  
As of February 2021 , multiple clinical trials have been reporte d, providing early gui dance to 
clinical providers on management of COVID -19, particularly in the hospital setting. One drug 
has been approved by the FDA for use in the inpatient setting  (remdesivir) and one has been 
FDA approved for years (dexamethasone) ; both have been reporte d to improve clinical disease 
and in the case of dexamethasone, mortality . [10, 11]  Numerous medications are currently under 
investigation including  monoclonal antibodies to spike protein and numerous 
immunomodulatory agents , including tocilizumab . No therapies have been approved for pre - or 
post-exposure prophylaxis  nor for therapy of outpatients, although there are several 
investigational agents authori zed for emergency use  by the FDA, including bamlanivimab, 
bamlaniv imab + etesevimab  in combination, and casirivimab + imdevimab  in combination . [12, 
13]   
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 20 2.3. Benefit/Risk Assessment  
The risks for participation in this study include  taking study drug  (see Appendices)  and loss of 
confidentiality . There may be some benefit to th e participant if the therapy is effective  against 
COVID -19. 
2.3.1.  Risk Assessment  
Loss of confidentiality risks: There is a potential risk of loss of confidentiality. Every effort will 
be made to protect the participant‚Äôs confidential medical information, but this cannot be 
guaranteed. Clinical information will not be released without written permission of the  
partic ipant, except as necessary for monitoring by the IRB, FDA, National Institutes of Health 
(NIH), Office for Human Research Protections (OHRP ), other local, US, and international 
regulatory authorities/entities as part of their duties.  
Risk lowering measures : Study procedures to manage and minimize risks include careful 
selection of the participants and monitoring over time to check on participants ‚Äô health. 
Additional guidance to manage any risks  or any change to the risk to the participant  based on 
emerging data  will be provided to the study teams, as needed. In addition, an independent 
Independent Data Monitoring Committee  (IDMC ) will monitor safety of the participants 
throughout the study.  
2.3.2.  Benefit Assessment  
Participants who randomize to a study drug  arm may benefit from study drug administration.  
There is no direct benefit to participants randomized to the placebo arm  apart from participating 
in generating evidence that may ultimately support treatment  for SARS -CoV-2 infection . In 
additi on, they will benefit from involvement with the team following their health status during 
the study. The knowledge gained will be a benefit to others in the future.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 21 3. Objectives and Endpoints  
Objectives  Outcome Measure ment s Reported Endpoint s 
Primary    
To evaluate the 
effectiveness of repurposed 
medications  [(study drug(s)] 
in reducing symptoms in 
nonhospitalized participants 
with mild to moderate 
COVID -19 The following will be evaluated 
from baseline through Day 14:  
ÔÇ∑ Hospitalization  
ÔÇ∑ Death  
ÔÇ∑ Symptom count  The following model -
assisted endpoints will be 
reported for the primary 
objective:  
ÔÇ∑ The odds ratio ( OR) 
describing the overall 
difference  in symptoms and 
clinical events over the 14 
days 
ÔÇ∑ The overall risk difference 
for hospitalization and 
death  
ÔÇ∑ Mean and median time to 
symptom resolution  
Secondary    
To evaluate the clinical 
outcomes  (e.g. 
hospitalization and death) in 
participants in a study drug 
arm versus those in the 
placebo arm  ÔÇ∑ COVID Clinical Progression  
Scale on Day 7, Day 14, and 
Day 28 (see Section 8.2) 
ÔÇ∑ Hospitalization or death 
through Day 28  
ÔÇ∑ Mortality through Day 28  
ÔÇ∑ Hospitalization, urgent care 
visit, emergency room visit 
through Day 28  The following model -
assisted endpoints will be 
reported for the COVID 
Clinical Progression Scale : 
ÔÇ∑ The OR describing the 
overall difference  in 
clinical progression  
ÔÇ∑ The OR describing the 
difference in clinical 
progress ion at each 
measured time point  
ÔÇ∑ The overall risk difference 
for hospitalization or death  
The following endpoints for 
the composite of 
unscheduled medically 
assisted care will be  
estimated:  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 22 ÔÇ∑ The overall risk difference 
for any of urgent care, 
emergency care, 
hospitalization or death  
ÔÇ∑ Time to first urgent care, 
emergency care, 
hospitalization or death  
ÔÇ∑ Risk and time to event for 
each component of the 
composite  
To describe symptom 
resolution in participants in 
a study drug arm versus 
those in the placebo arm  Symptom resolution, defined as 
first of at least three co nsecutive 
days without symptoms  Directly measured mean and 
median t ime to symptom 
resolution  
To describe the quality of 
life (QOL) in participants in 
a study drug arm versus 
those in the placebo arm  Modified Patient -Reported 
Outcomes Measurement 
Information System (PROMIS) -
29 at baseline, Day 7, Day 14, 
Day 28, and Day 90 Follow -up Model -assisted endpoints 
will be reported for QOL 
scores:  
ÔÇ∑ Overall OR  
ÔÇ∑ Odds ratios ( ORs) specific 
to days 7, 14, 28 and 90  
ÔÇ∑ Mean difference in QOL 
scores at each time point  
Exploratory    
To describe long -term 
COVID -19-related 
symptoms in participants in 
a study drug  arm versus 
those in the placebo arm  Symptom occurrence, type, and 
severity at Day 90 Follow -up 
 Directly measured m ean and 
median symptom count and 
QOL score at Day 90 in 
study drug arm(s) versus 
placebo.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 23 4. Study Design  
Refer to Section 1.2 for the Study Schema.  
4.1. Overall  Design  
This study is a platform  protocol designed to be flexible so that it is suitable for a wide range of 
settings within healthca re systems and in community settings where it can be integrated into 
routine COVID -19 testing programs and subsequent treatment plans. The platform  protocol will 
enroll participants  with mild to moderate COVID -19 in an outpatient setting with a confirmed 
PCR or antigen test  for SARS -CoV-2 infection . Each appendix will describe a repurposed 
medication ( study drug  arm) that is sized to meet the master protocol objectives.  
Participants will be randomized based on the study drug  appendices  that are actively enr olling at 
the time of randomization. Study drug  appendices  may be added or removed according to  
adaptive design and/or  emerging evidence. When there  are multiple study drug appendices  
available, randomization will occur based on appropriateness of each drug for the participant  as 
determined by the study protocol and investigator  and participant equipoise . Each participant 
will be required to randomize to at least one study drug versus placebo.  The probability of 
placebo to treatment will remain the same regardless of eligibility  decisions.   
Eligible participants will be randomized (1:1), in a blinded fashion, to either the study drug  
arm or placebo arm  in addition to standard of care . As additional study drug  appendices  are 
added, the randomization will be altered to leverage placebo data across arms. Participants 
will receive a complete supply of repurposed medication (study drug) or placebo  with the 
quantity  depending on the study drug/placebo  to which  they are randomize d. 
All study visits are designed t o be remote. However, screening and enrollment may occur in -
person at sites and unplanned  study visit s may occur in -person  or remotely , as deemed 
appropriate by the site investigator  for safety purposes . Participants will be asked to complete 
questionnaires and report  safety events  during the study, according to Table 1. Participants will 
be prompted b y the online system to report safety events and these will be reviewed and 
confirmed via medical records and site staff, as necessary .  
4.2. End of Study  Definition  
A participant is considered to have completed the study if he/she has completed the Long -term 
Follow -up assessments at 90 days . 
The end of the study is defined as the date of the last follow -up of the last participant in the 
study . Data from interim analyses or recommendations  by the IDMC  may result in protocol 
modifications or early term ination of the study.   
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 24 5. Study Population  
All Eligibility Criteria will be obtained per participant.   
5.1. Inclusion Criteria  
1. Completed Informed Consent  
2. Age ‚â• 30 years old  
3.   Confirmed SARS -CoV-2 infection by any authorized  or approved polymerase chain 
reaction  (PCR ) or antigen  test collected within 10 days of screening  
4. Two or more c urrent symptoms of acute infection for ‚â§ 7 days. Symptoms include the 
following:  fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches , chills, 
headache, sore throat, nasal symptoms, new loss of sense of taste or smell  
5.2. Exclusion Criteria   
1. Prior diagnos is of COVID -19 infection  (> 10 days from screening)  
2. Current or recent (within 10 days of screening) hospitalization  
3. Current use of study drug or study drug/device combination *  
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or 
placebo * 
5. Known contraindication (s) to study drug  including prohibited concomitant medications 
(see Appendices) * 
*If only one study drug appendix is open at the time of enrollment. If multiple study drug 
appendices are open, a participant may opt -out of any study drug appendix or be 
excluded from any study drug appendix based on contraindications listed in the study 
drug appendix , curr ent use  of study drug , or known allergy/sensitivity/hypersensitivity 
and still remain eligible for the remaining study drug appendices.  
5.3. Recruitment and Engagement  
5.3.1.  Participant Recruitment  
Participants who are eligible based on positive SARS -CoV-2 PCR or antigen test will be 
identified by participating sites  or will self -identify to a central study hotline (s) and be referred to 
the closest site . Site investigators, or their designee, may contact eligible participants to introduce 
the study and discu ss study participation.  
5.3.2.  Participant Engagement  
Participants will be engaged in the study  through  multiple channels. This includes , but is not 
limited to , ongoing participation in other registries partnering with ACTIV or healthcare systems.  
Additionally,  participant engagement will include:  
ÔÇ∑ compensation for participants who complete the Day 90 Final Visit;  
ÔÇ∑ creating a study -wide ACTIV -6 Advisory Group;  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 25 ÔÇ∑ developing participant -centered approaches that recognize the needs and preferences of 
COVID -19 survivors locally  and nationally ; and 
ÔÇ∑ multifaceted approaches that combine engagement tool s, leverage the online system , use 
of social media , and representative COVID -Participants . 
5.3.3.  Participant Randomization  Process  
This trial is a double -blind, placebo -controlled trial. Pa rticipants and investigators will be  
blinded. A participant who is eligible for m study drug arms /appendices  will be randomized m:1 
study drug  to placebo ( Figure 1). The participant will then be randomized with 1/ m probability to 
each of the study drug appendices . A participant entering a study drug appendix  carries their 
study drug  or placebo designation with them and will get either the study drug  or matching 
placebo. Participants who receive placebo will be pooled across study drug arms for those study 
drug arms /appendices  that the participant is eligible. This reduces overall sam ple size by 
facilitating sharing of data from concurrent controls while maintaining a 1:1 allocation to study 
drug or placebo.  Randomization sequences will not be pre -generated. Given the adaptive nature 
of the trial and the unknown number of study drug  appendice s, arm assignment will be 
implemented at the time of confirming eligibility for randomization  using a random number 
generator. The participant eligibility criteria will be checked for each study  drug appendix , and 
the randomization probabilities wil l be set. The two step procedure will then occur, and the 
assignment to both study drug appendix  and study drug  versus placebo will be made. The 
participant and study teams will know w hich study drug appendix  the participant is allocated to , 
but will be blinded to study drug versus placebo  because they will be matching.  
The participant, treating clinicians, and study personnel will remain blinded to study drug versus 
placebo  assignment until after the database is locked and blinded analysis is completed.  Only the 
biostatistical team who is preparing closed IDMC  interim reports will be unblinded. Specifically, 
study drug/placebo  will be dispensed with packaging and labelling that would blind treatment 
assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician . Refer to the Manual of Procedures (MOP) for further details.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study , who 
fulfill  inclusion and exclusion criteria,  but are not subsequently  randomized . A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participant s to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities.   
Individuals who are considered screen failures  may not be re -screened.  
5.5. Enrollment  
Participants who are randomized and receive study drug/placebo will be considered en rolled. 
Participants who are randomized, but do not receive study drug/placebo for any reason (e.g. 
study drug lost in the mail), will not be considered enrolled on the study and will be identified as 
consented not enrolled . 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 26 6. Study Drug (s) 
6.1. Repurposed Medica tion Treatments  
See Appendices  
6.2. Placebo  
See Appendices  
6.3. Study Drug Accountability  
Use of study drug will be tracke d via the online system , call center , or sites . Participants will 
dispose of any unused study drug as they would normally when stopping a medication.  
6.4. Concomitant Therapy  
Select concomitant medications of interest  that the participant is receiving at the time of 
enrollment or receives during the course of the study  will be recorded along with  dosing 
information. Select c oncomitant medications  of interest include the following  and will be 
verified at each remote visit by designated study personnel : 
ÔÇ∑ Any t herapeutics that is thought to have potential  or purported COVID activity  including 
hydroxychloroquine   
ÔÇ∑ Antibiotics  
ÔÇ∑ Antifungals  
ÔÇ∑ Antiparasitic  
ÔÇ∑ Antivirals including HIV protease inhibitors and ribavirin  
ÔÇ∑ Immunosuppressants including s teroids  
ÔÇ∑ Angiotensin -converting -enzyme ( ACE )/angiotensin II receptor blockers 
(ARB )/angiotensin receptor neprilysin inhibitor ( ARNI ) 
ÔÇ∑ Statin 
ÔÇ∑ Anticoagulants and antipla telets  
ÔÇ∑ COVID -19 vaccine (before, during, or after study intervention)  
Refer to the MOP for more details on concomitant therapy. Refer to the appendices for 
contraindicated  medications for each of the study drugs.  
6.5. Intervention  After the End of the Study  
No additional study drug will be provided to the participant following completion of the study.   
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 27 7. Participant Withdrawal /Termination and Study Termination  
7.1. Participant Withdrawal/Termination  
Participants will be followed until participant closeout, withdraw al of consent, or death.  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons. This is expected to be uncommon.  
Those who request withdraw al from the study will be asked to continue on study follow -up with 
limited participation through the Final Visit ( Section 8.1.4 ). Limited participation may include a 
call(s) to assess safety  at study visits following withdrawal . 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected befor e such a withdrawal of consent.  
7.2. Premature Termination or Suspension of the Study  
The study  may be temporarily suspend ed or prematurely terminated if there is sufficient 
reasonable cause. Written notificati on will be provided documenting reason for study suspension 
or termination to the investigators, funding agency, and regulatory authorities , as appropriate . 
Circumstances that may warrant termination or suspension include, but are not limited to:  
ÔÇ∑ Determination of unexpected, significant, or unacceptable risk to participants  
ÔÇ∑ Insufficient compliance to protocol requirements  
ÔÇ∑ Data that are not sufficiently complete and/or evaluable  
ÔÇ∑ Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes  
ÔÇ∑ Recommendation by the IDMC  
7.3. Lost to Follow -up 
Participants will be asked for proxy contacts to assess vital status and/or other clinical events , 
including safety,  if a participant fails to provide the informatio n. Provision of proxy information 
is not required for study participation. A participant  will be considered lost to follow -up if he or 
she repeatedly fails to  complete study assessments/procedures  as outlined below  and neither the 
participant nor the parti cipant‚Äôs  proxy can be contacted by the study site.  
The following actions must be taken if a participant  fails to provide baseline  information, if they 
fail to complete daily symptom reporting by midnight the day after receiving the first dose of 
study drug /placebo  (Day 2) , if they miss two consecutive daily sympto m reportings  during Days 
3 to 14,  if they miss either the Day 14  or Day 28  Remote Visits, and/or they fail to complete the 
Day 90 assessments : 
ÔÇ∑ The site  or call center  must attempt to contact the participant  and counsel the participant  
on the importance of completing study assessments/procedures . 
ÔÇ∑ The site or call center will contact the participant‚Äôs proxy to assess vital status and/or 
other clinical or safety events.  
ÔÇ∑ The site or call center will attempt to collect all missing survey  responses . 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 28 ÔÇ∑ Before a  participant  is deemed lost to f ollow -up, the investigator or designee must make 
every effort to regain contact with the participant  (where possible, three  telephone calls 
and, if necessary , a certified letter to the participant ‚Äôs last known mailing address or 
local equivalent methods). These contact attempts should be documented in the 
participant ‚Äôs research  record . 
ÔÇ∑ Online obituary search .    
ÔÇ∑ Should the participant  continue to be unreachable , they will be considered lost to 
follow -up.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 29 8. Study Assessments and Procedures  
Screening and eligibility confirmation will be participant -reported. A positive SARS -CoV-2 test 
result must be verified prior to randomization (refer to the MOP for details ). Sites will be 
responsible for notifying the coordinating center for participant withdrawals, lost to follow -up, 
permanent cessation of study drug, study drug dose modifications  (if allowed, per Appendix) , or 
change in vital status. Data will be  collected directly from the participant and supported by 
medical records, as needed.  
  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 30 8.1. Schedule of Events   
 
Table 1: Schedule of Events  
 
                                              
 
 
 
1 Refer to study drug appendix for length of study drug administration.  
2 Only for enrollment in Study Drug Appendices that have pregnancy listed as a contraindication for females of 
childbearing potential. Participants will self -report pregnancy using the Pregnancy Reasonably Excluded Guide.  
3 Review only during study drug/placebo administration if contraindicated medications provided for the study drug 
arm, per Appendix.  
4 Day 14 only.  
5 Daily symptom reporting; continued daily beyond day 14 through day 28  until symptoms resolve for > 3 
consecutive days.  
6 Day 7 and 14 only.  
7 Day 3, 7, and 14 only.  
8 Participant‚Äôs medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse 
Device Events (UADEs) [as applicable], and Event s of Special Interest (ESIs).   
 
 
 
 
 
 
 
Procedures Screening  Intervention 
Period  Follow -up Period  Final 
Visit  Unplanned 
Study Visit  
Day 
Within 2 days 
of Day 1  
Day 1  
Days 2 -14 
 
Day 15 -
20 
Day 21 
¬± 2 days  
Day 22 -
27 
Day 28 
+ 5 
days  
Day 90 
+ 5 days  
 
ACTIV -6 Trial           
Consent  X         
Demographic Information  X         
Eligibility criteria confirmed  X         
Randomization  X         
Receipt of study drug or placebo   X        
Continued use study drug   Continuous1       
Clinical Assessments        
  
  
  
Abbreviated medical history  X         
Self-reported  Pregnancy  X2         
Concomitant Therapy  X X3 X3 
       
Remote Visit   X4    X   
Drug Adherence   X X 
       
COVID -19 Outcomes   X X6 
  X  X X  
Symptom Reporting  X5 X X5 
 X5 X5 X5 X5 X  
QOL Questionnaire  X  X6    X X  
At-home pulse oximetry    X7       
Safety Assessment8  Continuous via online system and medical record review  X 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 31 8.1.1.  Screening  
The following events will occur at Screening : 
ÔÇ∑ Consent : Participants will be consented either via an e -consent process  or paper process . 
The consent process should be done in accordance with local  and central  IRB regulations . 
Phone consenting may be facilitated through the e -consent or paper process.  
ÔÇ∑ Demographic information will be collected including , but not limited to,  age, sex, race,  
ethnicity , and  occupation  
ÔÇ∑ Eligibility criteria confirmation  by the participant via the online system  or by site staff via 
a paper process  
ÔÇ∑ Abbreviated medical history  
ÔÇ∑ Self-reported pregnancy, for women of childbearing potential ( only for enrollment in 
Study Drug Appendices that include pregnancy as a contraindication )  
ÔÇ∑ Concomitant therapy   
ÔÇ∑ Symptom reporting , daily  during screening period  
ÔÇ∑ QOL questionnaire  
ÔÇ∑ Randomization  (see Section 5.3.3 ) 
8.1.2.  Intervention Period  
The following events will occur during the Intervention Period, starting with receipt of study 
drug/placebo : 
Day 1:  
ÔÇ∑ Receipt of study drug or placebo  
ÔÇ∑ Study drug self -administration  (see Appendices for specific study drug/placebo 
administration)  
ÔÇ∑ Concomitant therapy   
ÔÇ∑ Drug adherence questionnaire  
ÔÇ∑ COVID -19 Outcomes  
ÔÇ∑ Symptom reporting  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
Days 2-14: 
ÔÇ∑ Study drug self -administration  (see Appendices for specific study drug/placebo 
administration)  
ÔÇ∑ Concomitant therapy , including contraindicated medications provided for the study drug 
arm, per Appendix , during study drug/placebo administration . 
ÔÇ∑ Remote  visit (Day 14 only ) 
ÔÇ∑ Drug adherence questionnaire , daily  
ÔÇ∑ COVID -19 Outcomes  (Day 7 and 14 only) 
ÔÇ∑ Symptom reporting , daily  
ÔÇ∑ QOL questionnaire  (Day 7  and 14  only) 
ÔÇ∑ At-home pulse oximetry readings  (Day 3, 7, and 14  only)  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 32 ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
8.1.3.  Follow -up Period  
Day 15 -20:  
ÔÇ∑ Symptom reporting, daily from Day 14 for participants who have not yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
Day 21 ¬± 2 days: 
ÔÇ∑ COVID -19 Outcomes  
ÔÇ∑ Symptom reporting , daily from Day 14 for participants who have not yet reported three 
consecutive days of no symptoms.  Participants who experience three days of 
improvement before  Day 14 but who then experience symptoms again will not be 
followed daily.  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
Day 22 -27:  
ÔÇ∑ Symptom reporting, daily from Day 14 for participants who have not yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
Day 28 + 5 days:  
ÔÇ∑ Remote visit 
ÔÇ∑ COVID -19 Outcomes  
ÔÇ∑ Symptom reporting , daily from Day 14 for participants who have not reported three 
consecutive days of no symptoms.  Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
ÔÇ∑ QOL questionnaire  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
8.1.4.  Final Visit  
Day 90 + 5 days:   
ÔÇ∑ COVID -19 Outcomes  
ÔÇ∑ Symptom reporting  
ÔÇ∑ QOL questionnaire  
ÔÇ∑ SAE, UADE (as applicable),  and ESI collection  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 33 8.2. Clinical  Assessments  
Abbreviated Medical History : smoking status, estimated body mass index ( BMI)/obesity, pre-
existing underlying lung disease  (e.g. chronic obstructive pulmonary disease , asthma, idiopathic 
pulmonary fibrosis ), underlying immunosuppression (transplant, malignancy, human 
immunodeficiency virus ( HIV), autoimmune disease), medical conditions that may increase risk 
of COVID -19 infections or complications ( e.g., diabetes, cardiovascular disease , hypertension, 
chronic kidney disease ), veno us thromboembolism, chronic liver disea se 
Concomitant Medications of Interest:  Concomitant medications of interest, including study drug 
specific contraindicated medications, will be collected. Refer to Section 6.4 for concomitant 
medications of interest and to the study drug specific appendices for contraindicated 
medications.  
Self-reported Pregnancy:  Participants will be asked to self -report pregnancy, as needed, per 
Study Drug Appendix. T he 3-item ‚ÄúPregnancy Reasonably  Excluded Guide‚Äù will be used to 
assess pregnancy at screening. The ‚ÄúPregnancy Reasonably  Excluded Guide‚Äù uses traditional and 
World Health Organization criteria to exclude pregnancy via participant self -report [14]. Refer to 
the MOP for details.   
Remote  Visit: Designated  study personnel will contact the participant directly via a phone call or 
other form of direct contact  (e.g. text or e -mail survey)  in order to conduct  study assessments , 
includ ing, but not limited to, COVID -19 outcomes, drug adherence (at Day 14), and safety 
events . A missed remote visit will be considered a protocol deviation  (non-major) . If a 
participant misses a remote visit, site study staff should take immediate action to c ontact the 
participant, per Section 7.3 follow -up processes. Refer to the MOP for details.   
Drug Adherence:  Adherence to the study drug administration schedule will be collected via the 
online system  and confirmed at the Day 14 remote  visit. 
COVID -19 Outcomes : The COVID -19 outcomes  for this trial are based on the World Health 
Organization‚Äôs Ordinal Scale for Cl inical Improvement and  will be collected via the online 
system  and from the medical record . [15] The following outcomes will be assessed  as part of the 
COVID Clinical Progression  Scale :   
0. No clinical or virological evidence of infection  
1. No limitation of activities  
2. Limitation  of activit ies 
3. Hospitalized , no oxygen therapy  
4. Hospitalized , on oxygen by mask or nasal prongs  
5. Hospitalized , on non-invasive ventilation or high -flow oxygen  
6. Hospitalized , on intubation and mechanical ventilation  
7. Hospitalized, on ventilation + additional organ support ‚Äì pressors, RRT, ECMO  
8. Death  
Symptom Reporting:  Symptoms and symptom -related responses will be reported by the 
participant via the online system . Additional symptom reporting may occur from the sites, as 
available.  Each of pre-defined symptoms will be assessed on an ordinal severity scale of none, 
mild, moderate, and severe.  The following symptoms will be collect ed:  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 34 ÔÇ∑ Fatigue  
ÔÇ∑ Dyspnea - shortness of breath or difficulty breathing at rest or with activity  
ÔÇ∑ Fever  
ÔÇ∑ Cough  
ÔÇ∑ Nausea  
ÔÇ∑ Vomiting  
ÔÇ∑ Diarrhea  
ÔÇ∑ Body aches  
ÔÇ∑ Sore throat  
ÔÇ∑ Headache  
ÔÇ∑ Chills 
ÔÇ∑ Nasal symptoms  
ÔÇ∑ New l oss of sense of taste or smell  
ÔÇ∑ Other COVID -related symptom   
At-home pulse oximetry measurements : Participants will provide pulse oximetry readings using 
a study -provided  FDA -approv ed pulse oximeter. Two consecutive pulse oximetry readings must 
be reported at each required timepoint. Day 3, 7, and Day 14 are study -required timepoints for 
pulse oximetry readings. Participants can report pulse oximetry readings at other times 
throughou t the study, at their own discretion.   
8.3. Quality of Life Questionnaires  
The following Q OL questionnaire will be used in this study:  
ÔÇ∑ Modified PROMIS -29: PROMIS  measures were developed through a collaborative 
process funded by the NIH.  [16] The PROMIS -29 consists of seven health domains with 
four 5-level items  associated with each and a pain intensity assessment using a 0 -10 
numeric rank. The seven health domains include physical function, fatigue, pain 
interference, depressive symptoms, anxiety, ability to participate in social roles and 
activities, and sleep disturbance . [17] The PROMIS -29 measures will be modified for this 
study and will include select questions from each of the seven health domains, refer to the 
MOP for details.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 35 9. Safety Assessments  
9.1. Adverse Events and Serious Adverse Events  
An AE is any untoward medical occurrence in humans, whether or not considered drug -related, 
which occurs during the conduct of a clinical trial. An AE can therefore be a ny change in clinical 
status, routine labs, x -rays, physical examinations, etc., that i s considered clinically significant by 
the study investigator .  
An SAE or serious suspected adverse reaction or serious adverse reaction  as determined by the 
investigator or the sponsor is an AE that results in any of the following serious outcomes:  
ÔÇ∑ Death   
ÔÇ∑ Life-threatening AE (‚Äúlife -threatening‚Äù means that the study participant was, in the 
opinion of the investigator or sponsor, at immediate risk of death from the reaction as it 
occurred and required immediate intervention)  
ÔÇ∑ Persistent or significant incap acity or substantial disruption of the ability to conduct 
normal life functions  
ÔÇ∑ Inpatient hospitalization or prolongation of existing hospitalization  
ÔÇ∑ Congenital abnormality or birth defect  
ÔÇ∑ Important medical event that may not result in one of the above outcomes, but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event  
Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline does not meet the definition of an SAE. Hospitalization is defined as a stay in the 
hospital exceeding 24 hours.  
An unexpected AE is defined as any AE, the specificity or severity of which is not con sistent 
with the package insert . 
9.1.1.  Adverse Device Effect (ADE) and Unanticipated Adverse Device Effect (UADE)  
For those repurposed medications that are a part of a combination product, which includes a drug 
and a d evice, the following additional definitions will apply . 
An ADE is an AE related to the use of an investigational medical device. This includes any AE 
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the 
implantati on, the installation, the operation, or any malfunction of the repurposed  medical 
device. This also includes any event that is a result of a use error or intentional misuse.  
ÔÇ∑ Device malfunction ‚Äì the failure of a device to perform in accordance with the 
instructions for use or clinical investigative plan.  
ÔÇ∑ User error  or intentional misuse - A device is used in a manner that is an act or omission 
of an act that results in a different medical device response than intended by the 
manufacturer  or expected by the user.  
A UADE is any SAE caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational 
plan or applications (including a supplemental plan or appli cation), or any other unanticipated 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 36 serious problem associated with a device that relates to the rights, safety, or welfare of 
participants.  
Unanticipated Adverse Device Effects  (UADEs)  will include events meeting either A or B as 
stated below:  
A. Events meeting ALL of the following criteria:  
ÔÇ∑ Not included in the relevant appendices or Product Label  
ÔÇ∑ Related to the device per site PI and/or IND sponsor  
ÔÇ∑ Serious (meets any of the following criteria):  
o Is life -threatening illness or injury  
o Results in permanent i mpairment of a body function or a body structure  
o Necessitates medical or surgical intervention to prevent permanent 
impairment of a body function or a body structure  
o Results in hospitalization  
o Led to fetal distress, fetal death, or congenital abnormality o r birth defect  
o Led to death  
(Permanent means irreversible impairment or damage to a body structure or function, exclu ding 
trivial impairment or damage ). 
B. Any other unanticipated serious problem associated with the device that relates to the 
rights, safety, or welfare of participants.  
9.1.2.  Collecti on Period for  AE and SAE Information  
Study participants (and their designated emergency proxies) will be instructed to report ESIs, 
SAEs , and UADEs  through their access t o the study‚Äôs online system . Each day for 14 days, the 
participant will be  asked to report on their symptoms and health state, including hospitalization  
and/or other change in health condition . The assessments include specific questions pertaining to 
ESIs, as well as symptoms  and seve rity, health care visits, medications and a notification to the 
participant to contact the study team with any concerns or questions. If the participant is still 
report ing symptoms at Day 14, they will continue to be assessed until they have experienced 
three consecutive days without symptoms, or until Day 28, whichever is shorter. At Day 28 and 
at Day 90, participants will complete assessments . Safety reporting will be available to the 
participant continuously throughout the study, but will only be require d at the aforementioned 
collection points.   
The daily and follow -up assessments , as described in the paragraph above,  will be monitored  and 
sites will be actively notified of events requiring review, including for reporting that meets 
criteria for ESIs, SAEs, or UADEs . Refer to the MOP for details.  In addition, participants will be 
invited during assessment s to request contact from the study team, or to report any unusual 
circumstances that might be relevant, if they so wish. Failure to complete daily as sessments is 
also a trigger for review of a possible SAE. A missed assessment  on the day after receiving  the 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 37 first dose of  study medication (Day 2) or any two consecutive days of missed assessments  up to 
Day 14 will prompt a notification to the site to con tact the participant.  
All participants will be instructed to self -report concerns either via an online event reporting 
system, by calling the site, or by calling a 24 -hour hotline. Participants will have access to event 
reporting via the online system  from the signing of the informed consent form (ICF)  until the 
Final Visit (Day 90). 
Events of special interest (ESIs) and SAEs  will be  extracted by site person nel from the 
participant‚Äôs medical record  if the participant seeks medical care or if hospitalization  occurs , 
each of which notifies the site  to conduct follow up .  
Medical occurrences that begin before the start of study drug/placebo , but after obtaining 
informed consent , will not be considered an AE. 
Non-serious AEs  (or ADEs, as applicable)  may be reported by the participant, but will not be 
further assessed by the site or study personnel unless the event meets the criteria of an ESI.  
Events of Special Interes t (ESIs) , SAEs , and UADEs (as applicable)  will be collected from the 
start of study  drug/device combination  until the Final Visit (Day 90) or until 30 days after the 
last dose /use of device  if participant terminates the study  early . 
9.1.3.  Assessing Causality of a Serious Adverse Event  
If an SAE occurs, t he site investigator  or medical monitor  will assess the relationship to study 
drug by using the following criteria:  
ÔÇ∑ Related:  
o Study drug - there is a temporal relationship between study drug  and event onset 
or the event abates when study drug is discontinued or known to occur with study 
drug. 
o Device ‚Äì an event is due to the use of the device and cannot be reasonably 
explained by an alternative cause.  
ÔÇ∑ Not related: The event has no temporal relationship to study drug  (or study device, as 
applicable)  or the AE  (or ADE, as applicable)  has a much mo re likely alternate etiology 
or is due to an underlying or concurrent illness or effect of another drug  (or device, as 
applicable) . 
9.1.4.  Reporting and Monitoring of SAEs  
All of the study drugs used in this platform  protocol are repurposed medications that are 
approved for marketing in the US  for another medical condition . However, their investigational 
use for treatment  of COVID -19 infection is not an approved indication and will be under an IND 
and subject to IND regulations in 21 CFR 312. The IND sponsor or de signee will review SAEs 
weekly, and will perform aggregate reviews of SAEs every two weeks. The IND sponsor or her 
designee will be responsible for determining if the safety reporting criteria are met per 21 CFR 
312.32(c)(1)(i)( C) and 21 CFR 312.32(c)(1)(i v) and will notify the Data Coordinating Center 
(DCC ) to prepare an aggregate report for submission to the FDA. An aggregate safety report will 
be submitted to FDA as soon as possible, but in no case later than 15 calendar days after the IND 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 38 sponsor determ ination. If the IND sponsor determines that an unexpected fatal or life -threatening 
suspected adverse reaction occurs markedly more frequently in a study drug arm than in the 
placebo arm, an aggregate safety report will be submitted to the FDA as soon as p ossible, but in 
no case later than 7 calendar days after the IND sponsor determination. Information on 
individual SAEs will be available upon request from the Agency following the submission of any 
aggregate reports.  
Any UADE(s) that the IND sponsor determ ines is/are reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all participating investigators within 10 working days of 
when the sponsor makes that determination.  
If the IND sponsor determines that a  UADE presents an unreasonable risk to participants, all 
investigations or parts of investigations presenting that risk shall be t erminated as soon as 
possible. Termination shall occur not later than 5 working days after the sponsor makes this 
determinatio n and no later than 15 working days after the sponsor first received notice of the 
effect.  
All hospitalization and death events will be adjudicated (see Section 10.9), any event that is 
determined to be COVID -19-related will not be reportable as an expedited SAE, with the 
exception of events that are related to study drug and unexpected, which will be reportable 
regardless of relatedness to COVID -19. All events that ar e not COVID -19-related per the 
adjudication process will be reviewed by the DCRI Safety Medical Monitor to determine if the 
event is a reportable SAE.  
Individual S AEs and UADEs must be entered into the data system within 24 hours of site 
awareness. The DCR I Safety Surveillance  team  will notify pharmaceutical partners of SAEs 
within 1 business day of their receipt that occur involving the specific appendix  of the supplied 
study drug/placebo,  as required.  Serious Adverse Events that are related and confirmed unlisted 
by the DCRI Safety Medical Monitor will be reported to the FDA  as SUSARs ; as 7-day reports 
for unexpected fatal or life -threatening adverse reactions and 15 -day reports for serious and 
unexpect ed adverse reactions. If the IND sponsor, IDMC , or FDA note a clinically important 
increase in the rate of a SUSAR, the IND sponsor or her designee will notify investigators no 
later than 15 calendar days after determining that the information qualifies fo r reporting.  The 
investigator will follow all reportable events until resolution, stabilization or the event is 
otherwise explained. The DCRI Safety Surveillance Team will follow all SAEs until resolution, 
stabilization, until otherwise explained.  
Pregnanc ies that occur while on -study will be collected and will not be followed to outcome  if 
outcome occurs beyond the participant‚Äôs Final Study Visit , however, any associated ESI or SAE 
should be reported if information can be collected and entered into the EDC . The DCRI Safety 
Surveillance team will notify pharmaceutical partners of a pregnancy within 1 business day of 
receipt that occur involving the specific appendix of the supplied study drug/placebo,  as 
required.  
9.1.5.  Events of Special Interest  
The following are also considered E SIs to the study  and will be collected by study personnel via 
medical record review  when concern for ESIs are observed for hospitalized  participants :  
ÔÇ∑ Hypoxia, defined as two consecutive pulse oximetry readings ‚â§ 93%  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 39 Each study drug ma y have a unique list of possible related ESIs. Refer to the relevant 
appendices.  
9.2. Unanticipated Problem (UP) and Terminations  
9.2.1.  Definition of Unanticipated Problem   
The OHRP considers UPs involving risks to participants or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
ÔÇ∑ Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protoc ol and informed consent document; and (b) the characteristics of the participant 
population being studied.  
ÔÇ∑ Related or possibly related to participation in the research (‚Äúpossibly related‚Äù means there 
is a reasonable possibility that the incident, experienc e, or outcome may have been 
caused by the procedures involved in the research).  
ÔÇ∑ Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
9.2.2.  Reporting of an Unanticipated Problem   
The site investigator will report UPs for their participants to the DCC. The site may also be 
required to inform their reviewing IRB about a UP occurring at the local institution. The UP 
report to the DCC wi ll include the following:  
ÔÇ∑ A detailed description of the event, incident, experience, or outcome  
ÔÇ∑ An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP  
ÔÇ∑ A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP  
ÔÇ∑ The DCC  will document and review all UPs.  Details of the UP reporting process will be 
located in the MOP.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 40 10. Statistical Considerations  
10.1. Statistical Hypotheses  
10.1.1.  Primary Hypothesis  
The primary hypothesis in this trial is that participants who receive study drug will have 
improved COVID -19 symptoms as compared to those who receive placebo.  
10.2. Sample Size Determination  
This study is designed to be analyzed using a Bayesian appr oach, accepting the possibility of 
adding and dropping of arms as the trial progresses. There is also the potential for extending 
accrual in a study  drug appendix  if there is the potential to demonstrate benefit on clinical 
events. Detailed simulations wil l be used to demonstrate the operating characteristics of each 
study drug appendix . Decision thresholds will be set to balance overall power with control of 
the Type I error rate. To aid planning for this trial, symptom count  and clinical event data were 
estimated from participants in a clinical trial with similar inclusion criteria. Data were not 
collected daily in that study, but evaluations were completed on Day 10 after randomization, 
which is considered a clinically meaningful point in time. Based on t he observed distribution, it 
is estimated that  studies of about n= 600 (300 study drug and 300 placebo)  will be sufficiently 
sized to determine whether there is evidence of meaningful benefit with >85% power ( Table 2). 
Moreover, when a  study drug  demonstrates overall effectiveness, the planned adaptations to 
increase targeted accrual for the purpose of demonstrating benefit on clinical events is a 
reasonab le extension within the context of this platform. This study will enroll up to 15,000 
adults, depending on the number of study drug  appendice s that are added and adjustments to 
sample size depending on the data.  [18]  
Table 2: ACTIV -6 Sample Size Estimates and Power  
OR Corresponding 
difference in mean 
symptom burden  Power  Corresponding Risk 
Difference in clinical 
events  Power  
80%  85%  90%  80%  85%  90%  
0.4 2.10 75 86 101 0.025  343 392 459 
0.5 1.98 132 150 176 0.021  455 520 608 
0.6 1.86 242 277 324 0.017  675 772 903 
0.7 1.74 496 567 664 0.012  1004 1148 1343 
0.8 1.61 1267 1449 1696 0.009  1652 1889 2211 
The sample sizes given are the sample size for the study drug  arm only. Placebos will be borrowed across study drug 
appendices . The total size of the placebo arm will be equal to the size of the study drug  arm. The total number of 
placebos in the trial will depend on eligibility of participants among the study drug appendices  and the number of study 
drugs . The calculations are ba sed on symptom burden, hospitalization, and death at Day 10.  
10.3. Randomization  
See Section 5.3.3  for additional details.   
10.4. Blinding  
The investigators , treating clinicians, and study participants  will all remain blinded to study drug  
versus placebo  assignment until after the database is loc ked and blinded analysis is completed. 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 41 Only the Investigational Drug Service  (IDS) and staff who are handling randomization codes and 
unblin ded member s of the biostatistical team who are preparing closed IDMC  interim reports 
will be unblinded. The statistical staff responsible for preparing IDMC  reports will not directly 
interact with the clinical team that delivers care to the study participants. Specifically, study 
medication will be dispensed with packaging  and labelling that would blind treatment 
assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician.  
The web-based randomization system  will include  blind-breaking instructions. Partici pant safety 
must always be the first consideration in making an unblinding determination. If the investigator 
decides that unblinding is warranted, the investigator should contact the IDS that shipped study 
drug/placebo  for unblinding a participant‚Äôs inter vention assignment .  
10.5. Populations for Analyses  
Modified Intention to Treat ( mITT) Population:   
‚óè All participants  who receive  study drug /placebo . 
‚óè Participants who do not receive study drug, for any reason, will be excluded ; while this 
modifies the intent ion to treat principle,  the failure of delivery of medications from site to 
participant is not under the control o f either investigator nor participants and is expected 
to occur infrequently and randomly. All other participants will be included, and they will  
be analyzed according to which arm they were assigned. Thus, the mITT analysis set 
includes all participants  who were randomized and received the study drug.  
Safety Population:  
‚óè The s afety population will include those persons in the  mITT popula tion who re port 
taking at least one dose of study drug or matching placebo . In the unlikely case a 
participant receives the incorrect study drug, participant s will be grouped according to the 
treatments that they received.  
10.6. Statistical Analyses  
The Statistical Analysis Plan ( SAP) for a study drug appendix  will be finalized prior to the first 
interim analysis.  It will include a more technical and detailed description of the statistical 
analyses outlined in this section, including detailed simulations used to info rm the sample size 
estimates. This section is a summary of the planned statistical analyses of the most important 
endpoints including primary and secondary endpoints.  
10.6.1.  General Considerations  
Baseline demographic and clinical variables will be summarized for  each randomized arm of the 
study. Descriptive summaries of the distribution of continuous variables will be presented in 
terms of percentiles (e.g., median, 25th and 75th percentiles) along with means and standard 
deviations. Categorical variables will be  summarized in terms of frequencies and percentages. 
Histograms and boxplots may be used to visualize the data.  
The primary analysis for this study will use a covariate adjusted statistical model . The primary 
outcome is an ordinal variable, which is the co unt of symptoms with hospitalization added as the 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 42 count of symptoms plus one, and death as the count of symptoms plus two . The outcome is 
measured daily for 14 days. The outcome is compared between participants receiving study drug 
and participants receivi ng placebo  each of the 14 days using a longitudinal statistical model that 
takes into account the repeated  measurements on each participant. The statistical model produces 
a common OR, which  is directly associated with the concordance probability  or the Wilcoxon -
Mann -Whitney U -statistic . This is the main quantity, or estimand, that will be used to make an 
overall claim of effectiveness in this trial .  
10.6.2.  Statistical modeling  
Estimation and inferences about the effect of each study drug versus matching placebo will be 
made using Bayesian proportional odds logistic regression methods. For each study drug, the 
matching placebo arm will consist of concurrently randomized participants that meet the 
inclusion and exclusion criteria for that study drug.  
The ge neral form of the Proportional Odds - model can be stated in terms of covariates X and an 
outcome variable Y, where probabilities of outcome value y or greater are given by 
Pr(ùëå‚â•ùë¶|ùëã)=expit (Œ±ùë¶+ùëãŒ≤)‚Äàwhere Œ±ùë¶ is the intercept for outcome value  y and expit is the 
logistic (inverse logit) transformation . X contains baseline covariates and treatment. The 
coefficients Œ≤ represent the log OR associated with the effects of each adjustment variable, 
including arm assignment. Specifically, the OR represents the relati ve effect of study drug versus 
placebo on the odds Pr(ùëå‚â•ùë¶|ùëã)(1‚àíPr(ùëå‚â•ùë¶|ùëã)) ‚ÅÑ , for any value y. 
The proportional odds is attractive for the analysis of ordinal and quantitative response variables, 
such as the primary outcome, because they directly model the cumu lative distribution function 
from which the many summaries of the primary outcome in each study drug arm are easily 
derived. Example summaries are the probability of a participant being symptom free, and the 
probability of being hospitalized or worse.  
The proportional odds model can be extended to accommodate repeated measures over time for 
individual participants. A longitudinal framework allows one to model the course of disease. 
There are several approaches to taking into account repeated measurements, among which  a first -
order Markov state transition model for ordinal outcome provided the best fit to the correl ation 
structure found in data from the ORCHID trial. While these pa rticipants  had more severe  disease 
and the outcome was clinical in nature, the  same considerations  apply  to the within -participant  
correlation structure  for symptoms, hospitalization or death. The longitudinal ordinal 
proportional odds model  will be fit using a Markov state transition model.   
With a first -order Markov process, the o utcome on one day of measurement becomes the 
predictor for the next day of measurement. The model will also take absolute time (days from 
first dose of study drug ) into account because the mix of outcomes changes over time in a way 
that simple transition o dds ratios can not capture. The selected approach allows the correlation 
between states on two successive days to be high within pa rticipant, and it handles absorbing 
states such as death.  It also allows the consideration of different time intervals between  
measurements (if measurement days are missed).  
Markov models typically assume that the outcome variable is also assessed at baseline (time 
zero). This the case for ACTIV -6. Participants cannot inhabit the extremes of the scale at 
enrollment, and that is of no consequence. The main obstacle to using transition models is that 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 43 the primary model parameters (for the proportional odds model) at one time are conditioned on 
the previous state. The model will be restated to obtain probabilities of being in state y  or worse 
(‚Äústate occupancy probabilities‚Äù) through recursive (through time) matrix multiplications to 
‚Äúuncondition‚Äù the transition probabilities. Thus, the OR and the probability of being in any given 
state (or worse) can be provided for any day. The prob abilities will be leveraged for quantifying 
the effect of study  drugs  on symptom burden, hospitalization, and death.  For example, it is 
possible to state the probability of having more than 5 symptom s, the probability of being 
symptom free, or the probabil ity of being hospitalized or having died. These quantities are 
readily comparable between study drug and placebo participants  to place the  OR from the 
proportional odds model in context. In preliminary data used to explore observable effect sizes  
(Table 2), an OR of 0.6 would be observed as an absolute difference in the probability of being 
hospitalized or dying of 0.017 (1.7%) . 
State occupancy pr obabilities are functions of all model parameters. Because of that it is difficult 
to get confidence intervals and statistical tests using frequentist methods. The Bayesian approach  
will be used  to provide  exact inferences, taking all uncertainties into ac count. Graphical methods 
will be used to show the probability of a pa rticipant  being either symptom free, or of being 
hospitalized or worse, as a function of time and treatment (these figures are sometimes referred 
to as funnel plots). Various ways of rest ating the model results are also possible. For example, if 
considering the state occupancy probabilities for mortality, this would approximate a Cox 
proportional hazards model.  
The common OR will be used as the primary estimand for claims of effectiveness  in reducing 
symptom s. The probability of hospitalization or death will be used as the primary estimand for 
clinical efficacy. These are the primary estimands for decision making in this trial, and both they 
and their posterior distribution are readily computed using standard Bayesian methods. Mean  and 
median  time to symptom resolution  will be used to quantify the clinical benefit of symptom 
improvement.  
In the modeling, the proportional odds assumption will be checked. While the model is generally 
robus t, a check will be done for the possibility of a different treatment effect on clinical events 
than on symptoms and a partially proportional model will be used if it does differ. The time by 
treatment interaction  will also be checked  to determine whether t he OR changes during the  14-
day observation window . If it does, the decision making in this trial will be anchored to the OR 
observed on Day 14.  
10.6.3.  Model priors  
Prior distributions will be specified as follows:  
- Intercepts  are derived parameters from the mul tinomial outcome cell probabilities 
having a Dirichlet distribution with concentration parameter 1(‚ÅÑ0.80+0.35 max  (ùëò,3)), 
found to have excellent properties (here k = total number of outcome categories)  
- The covariate X is an indicator variable for being in  the study drug arm  (versus matching 
placebo), and the study drug  effect  (negative values indicate benefit) has a skeptical 
prior which is a normal distribution having mean zero and small standard deviation [ SD] 
(concentrating the treatment effect toward s zero) provided below.  

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 44 The mean zero prior for the study drug  effect  implies an equal chance of harm of the treatment 
as of benefit, consistent with equipoise.  The choice of the SD  of the prior distribution for  
further defines the skepticism of this effect in the following way. Assume that the investigational 
study drug  is not a cure but is rather an incremental therapy. This implies that the odds ratio OR 
  for the study drug  cannot be near zero (values < 1.0 indicate benefit).  Assume that the 
probability of a large benefit on the outcome severity, with large meaning an OR < 0.5, is only 
0.025, and to be symmetric the chance of large harm (OR > 2) is also 0.025.  Thus, the prior 
probability that the OR is in [ 0.5, 2] is 0.95. The prior SD  that achieves this level of skepticism 
is log (0.5)Œ¶‚àí1(0.025 ) ‚ÅÑ  where  denotes the standard normal cumulative distribution function . 
10.6.4.  Assessing Effectiveness  
The overall effect of each study drug versus matching placebo will b e quantified using the 
common OR from the proportional odds model (primary estimand). Evidence for efficacy will be 
quantified as the posterior probability that the OR is less than 0.9 . This is denoted the ‚Äúposterior 
probability for efficacy‚Äù or ùëÉ(ùëÇùëÖ<0.9|Data ). Similarly, the risk difference in hospitalization 
or death will be used to draw conclusions about clinical efficacy. Regardless of whether there is 
an efficacy signal, the following quantities will be reported from the model:  
ÔÇ∑ Mean and median time to symptom resolution  (for quantifying benefit on symptoms)  
ÔÇ∑ Mean and median time to hospitalization or death  (secondary outcomes)  
The primary analysis will be implemented separately for each study  drug, where the matching 
placebo arm will consist of concurrently randomized participants that meet the inclusion and 
exclusion criteria for that study drug . An mITT approach  will be used  for primary analyses. All 
available data will be used to compare each  study drug  versus placebo control, r egardless of 
post-randomization adherence to study protocols.  
10.6.5.  Planned Interim Analyses, Early Stopping, and Type -I Error Control  
Individual study drugs may require different sample sizes, and the sample sizes may be adjusted 
based on the results of interi m analyses. Therefore, fixed enrol lment triggers will be used for 
interim analyses. An interim analysis will occur after enrol lment and completion of 14 day 
follow up of approximately every 200 participants in a study arm  (100 in study drug arm and 100 
in placebo arm) . At each interim analysis, the study drug appendix  may be stopped early for 
efficacy or futility. Thresholds have been established to guide stopping of the trial if there is 
clear evidence of clinical benefit, there is evidence of equivalence,  there is evidence of symptom 
benefit but pursuing clinical benefit is futile, or if the study drug is harmful. The following 
decision thresholds will be checked at each interim analysis:  
i) The Study Drug is found to have benefit (efficacy): A posterior p robability of 
meaningful benefit (e.g. OR < 0.9) for a study drug in comparison to the placebo control 
of > 0.95 will result in a declaration of overall superiority.  
a. If a study drug arm is declared superior, a futility analysis will be 
conducted on observing clinical efficacy (reduction in hospitalizations or death) if 
the study drug arm were to continue for an additional one year. Accrual will be 
projected based on ac tual trial accrual and projected case rates. Stopping for 

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 45 futility will be strongly encouraged if the predicted probability of success (PPOS) 
is low (e.g. <0.1) and will be discouraged if the PPOS is high (e.g.>0.7).   
ii) The study drug is found to be sub stantially similar to the placebo control 
(inefficacy): A posterior probability of >0.95 that there is no more than trivial benefit 
(e.g. OR > 0.9) or harm of an arm will result in termination of that arm.  
iii) The study drug is found to cause harm (infer iority): A posterior probability of 
>0.85 for worse adverse clinical outcomes (hospitalization or death) for a study drug 
relative to the placebo control (e.g. a risk difference >0.01) will result in termination of 
that arm.  
iv) The predicted probability o f success of any study drug given expected accrual at a 
prespecified point in time will be provided to the IDMC . Stopping for futility will be 
strongly encouraged if the PPOS is low (e.g. <0. 1) and will be discouraged if the PPOS is 
high (e.g. >0.7).  Note  that unlike the probability of inefficacy, PPOS involves Bayesian 
posterior predictive distributions.  
Futility is a low probability of achieving any conclusions within a reasonable time frame or with 
available resources. Prior to each interim analysis, th e target date for study completion will be 
specified, and accrual will be projected by that target date. A statistical model may be used to 
predict accrual.  Futility assessment will use the lowest of either the planned accrual or predicted 
accrual at study  closure.  
The combination of decision thresholds and effect sizes have been selected to balance the ability 
to observe a meaningful effect on symptoms, to observe the potential for an effect on clinical 
outcomes, and to maximize power. In making decisions,  power  will be balanced  with the Type 1 
error rate. For each study drug, simulations will be used to demonstrate that the operating 
characteristics are consistent with a Type I error control of at least 5%.   
10.6.6.  Sensitivity and Supplementary Analyses  
The prop ortional odds assumption  of the model requires that the effect of treatment on the odds 
that Y ‚â• 3 (measured as an OR versus placebo) is the same relative effect as for Y ‚â• 4. Even 
when the proportional odds assumption is strongly violated, the estimated O R remains a simple 
function of the Wilcoxon -Mann -Whitney U -statistic, namely the probability that a randomly 
chosen pa rticipant on treatment B has a higher response than a randomly chosen pa rticipant on 
treatment A,45 the probability index or concordance probability . Thus, the proportional odds 
assumption is not necessary for the proportional odds model to provide a reasonable global 
assessment of treatment effectiveness, when the primary estimand is the OR. However, derived 
quantities such as the difference in medians may be more sensitive to violations of the 
proportional odds assumption. To asses s the robustness of inferences about the primary estimand 
with respect to the proportional odds assumption . This assumption will be relaxed  using  a 
partially proportional odds model as necessary . 
In addition to checking assumptions about the modeling appro ach, association of adherence with 
outcomes  will also be ascertained . In the main statistical mode l, the number of doses of study 
drug consumed  will be added  as a covariate . 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 46 10.6.7.  Differential Treatment Effects and Subgroup A nalyses  
Differential treatment effect , also referred to as heterogeneity of treatment effect, refers to 
differences in treatment efficacy as a function of pre -existing pa rticipant  characteristics such as 
baseline variables. This is often assessed by forming subgroups. However, these subgroups  do 
not inherit the baseline covariate adjustment of the full pa rticipant  outcome model, and are 
problematic because of improper subgrouping when a continuous variable is used. For example, 
dichotomizing age at 65 years is arbitrary and it is very unlikely  that any study drug  effect has a 
discontinuity in effect at 65 years old. Also, subgroup estimates and statistical assessments of 
them are unreliable and are often taken out of context when a more systematic analysis does not 
find evidence for an interact ion between the covariate and study drug .  
For these reasons, analysis of differential study drug  effect will be prespecified and model based.  
For example, effectiveness vari ability can be estimated with continuous age by adding a smooth 
age by study drug  interaction into the model and using this model and using this model to 
estimate treatment contrast and their uncertainties across age = 10, 11, ‚Ä¶, 100. Differential 
treatment effects by sex, body mass index, and age will be examined.  
Studies under this master protocol will be sized only for assessing overall study drug  effects. 
Thus, there may be inadequate power to (1) examine interactions and to (2) estimate covariate -
specific treatment effects (e.g., odds ratio at age 70 or for fema les). 
10.6.8.  Secondary Clinical Endpoint  
The COVID Clinical Progression  Scale score on Day 1 4 will be compared between participants  
in each study drug  arm and the placebo arm  using a covariate adjusted proportional odds model . 
A similar approach will be used for QOL outcomes. Covariates will be prespecified and will 
include at a minimum: age, baseline severity, and duration of illness . The proportional odds 
assumption will mainly be examined using graphical methods ‚Äîe.g., the logit of the empirical 
cumulative distribution function of the ordinal scale should be parallel among categories of 
covariates . If proportionality is clearly violated, a partial proportional odds or non -proportional 
odds models  will be considered . As before, a Bayesian approach to model in terpretation will be 
used. For estimating time to symptom resolution  based on the definition of at least three 
consecutive days without symptoms, a proportional hazards model will be used. Since death is a 
competing risk, cause -specif ic hazards  will be est imated . Observations will be censored at 28 
days.  
10.6.9.  Exploratory Analysis  
Exploratory analyses involve the same outcome variables, measured at 90 days. Exploratory 
analysis will focus on describing long term outcomes, particularly symptoms  and severity , 
clinical status , and QOL . Statistical models will use a similar form as for the main analysis. As 
well as simple analysis that consider the effect of treatment on long term outcomes, the SAP will 
describe how participant  state during the intervention period wil l be used to inform longer term 
outcomes.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 47 10.6.10.  Adherence and Retention Analysis  
Withdrawals from study drug  and consent withdrawals will be tracked via the online system .  
Participants will be asked about  their use of study drug . Those reporting discontinuation or 
switching will be asked about the reasons for discontinuation/switching.   
Measures of study retention to inform follow -up time will be based on several measures, 
including web-based check -ins for symptoms and COVID -19 outcome reporting . 
10.7. Interim Reporting   
In addition  to routine evaluation of decision thresholds pursuant to the statistical design of this 
study, regular IDMC  reviews will be conducted to ensure the safety of study participants.  
Regular IDMC  meetings will monitor the following parameters at a minimum:  
ÔÇ∑ Recruitment progress  
ÔÇ∑ Enrollment overall and by subgroups  
ÔÇ∑ Adherence, retention, and status of data collection  
ÔÇ∑ Events of special interest  (ESIs)  
ÔÇ∑ Unanticipated problems  
ÔÇ∑ Serious adverse events  (SAEs)  
Interim examination of clinical endpoints will be based on the accrual of primary endpoint data.  
It is expected that reviews of the data will occur approximately after each 200 participants  are 
enrolled in each study drug appendix (100 in study drug arm a nd 100 in placebo arm) .  
For ethical reasons, interim examinations of key safety and process data will be performed at 
regular intervals during the course of the trial. The  DCC  will create reports to track pa rticipan t 
enrollment, rates of adherence with th e assigned treatment strategy, and frequency of protocol 
violations. Prior to each meeting, the DCC  will conduct any requested statistical analyses and 
prepare a summary report along with the following information: pa rticipant enrollment reports, 
rates of adherence with the assigned treatment, and description of SAEs.  
Safety reports will be prepared for the IDMC  approximately weekly once enrollment begins. The 
prespecified stopping thresholds are intended to guide the interpretation of interim analyses and  
are not a strict rule for early termination.  It is expected that both internal and external factors will 
influence the decisions of the IDMC . The SAP will describe the planned interim analyses and 
futility monitoring in detail . 
10.8. Independent Data Monitoring  Committee  (IDMC ) 
The IDMC  will monitor participant safety and study performance. A n IDMC  charter that outlines 
the operating guidelines for the committee and the procedures for the interim evaluations of 
study data will be developed and agreed upon by the IDMC . Reports will be prepared by the 
DCC in accordance with the plan outlined in the ch arter, or as requested by the IDMC  chair, and 
will include interim analyses of primary and secondary endpoints, additional safety events, and 
other information as requested by the committee. After each scheduled closed meeting, the 
IDMC  will send a recomme ndation to the IND sponsor  to continue, modify , or terminate  the 
study. After approval, the recommendations will be forwarded by the clinical coordinating center 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 48 (CCC ) to investigators for submission to their local, regional and national IRB /Ethic 
Committe es, as applicable. Please refer to the  IDMC  Charter  for further details . 
10.9. Adjudication Committee  
The medical records  will be requested  for all participants reporting a hospitalization  and/or de ath 
at any point during the study. For each participant -reported  hospitalization  or death  event, t he 
DCRI Clinical Ev ent Ascertainment (CEA)  group will review the medical records and confirm 
the occurrence and root cause of the event as part of an adjudication process . The CEA group  
includes specialists relevant to the  hospitalization  or death  events of interest, additional details 
about review procedures will be provided in an adjudication charter.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 49 11. Ethical Standards  
11.1. Institutional Review Board (IRB)  
The protocol, ICF(s) , recruitment materials, and all participant materi als will be submitted to the  
IRB(s)  of record  for review and approval . This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol will require review and approval by the IRB(s) 
before being implemented in the stu dy. All changes to the consent form will also be IRB -
approved and a determination will be made regarding whether previously consented participants 
need to be re -consented.  
11.2. Informed Consent Process  
All consenting will occur either via an electronic consent process  or a paper process . Consent 
forms describing in detail the study drug/placebo , study procedures, and risks will be  given to the 
participant and documentation of informed consent is required prior to starting study procedures. 
Informed consent is a process that is initiated prior to the individual‚Äôs agr eement  to participate in 
the study and continues throughout the individual‚Äôs study participation. A description  of risks 
and possible benefits of participation will be provided to the participants. Con sent forms will be 
IRB-approved and the participant will be asked to read and review the document. The participant 
will be provided a phone number and email in the event they have questions about study 
participation. This will allow them to communicate wit h the investigator s (or their delegate) , for 
further  explana tion of the research study and to answer any questions that may arise , as 
necessary . Participants will have the opportunity to carefully review the consent form and ask 
questions prior to signing.  
The participants should have the opportunity to discuss the study and think about it prior to 
agreeing to participate. The participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the informed consent document will be 
provided  to the participants for their records. The rights and welfare of the participants will be 
protected by emphasizing to them that the quality of their medical care will not be adversely 
affected if they decline to participate in this study.  
The study team w ill distinguish between the desire to discontinue study drug and the desire to 
withdraw consent for study follow -up. In the event that a participant withdraws consent, the 
investigator or his /her designee will clarify with the participant and document whet her the 
withdrawal is temporary or permanent, and if a full or partial withdrawal.  
11.3. Participant and Data Confidentiality  
Participant confidentiality is strictly held in trust by the participating investigators, their staff, 
and the sponsor(s) and their agen ts. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical and private information relating to participants. Therefore, the 
study protocol, documentation, data, and all other information generated will be held i n strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor. The study participant‚Äôs contact 
information will be securely stored in the clinical study d atabase.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 50 Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DCC . The study data entry and study 
management systems used by clinical sites and by research staff w ill be secured and password 
protected. At the end of the study, all study -related data storage systems  will be archived  
according to local processes . 
11.4. Site Management and Quality Assurance  
The study team will work in tandem to ensure that the data collected  in this study are as complete 
and correct as possible. A four-step, multi -functional approach to quality control  will be 
implemented : 
ÔÇ∑ Training: Prior to the start of enrollment, the clinician investigators and key study 
personnel  at each site will be trai ned with the clinical protocol and data collection 
procedures, including how to use the Electronic Data Capture (EDC) system. Follow -up 
training and training for new study personnel or new versions of the protocol will be 
conducted as needed.  
ÔÇ∑ Monitoring: T he CCC, along with the DCC, will ensure that data collection is handled 
properly, will provide in -service training, and will address questions from site investigators 
and coordinators. Electronic r eview  of data quality and completeness  will occur  on a 
regular and ongoing basis. Any issues will be address ed. At a minimum, s ource document 
verification will occur, as needed, for confirmation of COVID -19 diagnosis and 
hospitalization(s).  
ÔÇ∑ Managing data: After the data have been transferred for statistical summarization, data 
description, and data analysis, further crosschecking of the data will be performed with 
discrepant observations being flagged and appropriately resolved through a data query 
system.  
ÔÇ∑ Reviewing data: Data regarding e vents of interest wil l be reviewed  to ensure appropriate 
documents are collected for DSMB review. The DCC will monitor standardized 
classification of symptoms  and contact site study teams when events comprising the 
primary endpoint  are not complete . 
11.5. Site Monitoring  
This study will employ a centralized risk -based approach to monitoring with routine and periodic 
review of participant -submitted data to validate the informed consent process, select eligibility 
criteria, hospitalization, identify and follow -up on missing data, incon sistent data, data outliers, 
etc. and ensure completion of administrative and regulatory processes.  The study team will 
facilitate regular communication through training sessions, teleconferences, videoconferencing, 
email, etc. Using quality -by-design prin ciples , steps  will be  taken at the study design stage to 
foresee and limit problems that might occur during the study conduct. Follow -up from the online 
system  and call center is expected to keep participants engaged. Minimal levels of intervention 
and a focus on observing rather than influencing the study participants greatly increases the 
likelihood that Good Clinical Practices will be followed. Central statistica l monitoring is 
particularly useful for identifying unusual patterns in data. An integrated approach to quality 
surveillance  will be deployed , which will be detailed in the appropriate study management plans.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 51 12. Data Handling and Record Keeping  
12.1. Data Collection and Management Responsibilities  
Minimizing research activities and conducting the trial in a pragmatic manner will increase the 
ability to complete the trial in the face of strained clinical and research resources during the 
COVID -19 pandemic. Data will be collected by electronic methods, supplemented by telephone 
or videophone follow -up and from the electronic health record.  
Data will be collected  directly from pa rticipants  using RED Cap through text messaging or email 
with a survey link, or pho ne call as back up. The process for using text messaging is Health 
Insurance Portability and Accountability Act ( HIPAA ) compliant.  
Site personnel  or participants will enter study data into a secure online database. Data will be 
maintained  in a secure onli ne database until the time of study publication. At the time of 
publication, the DCC will generate a de -identified version of the database  for archiving (see 
Section 12.4). 
12.2. Study Records Retention  
Study documents should be  retained for a minimum of six  years after the study has ended. 
However, if required by local regulations, these documents should be retaine d for a longer 
period. No records will be destroyed without the written consent of the sponsor, if applicable. It 
is the responsibility of the sponsor to inform the investigator when these documents no longer 
need to be retained.  
12.3. Protocol Deviations  
A protocol deviation is defined as  non-compliance with the  clinical study  protocol, GCP, or 
MOP requirements. The  non-compliance may be on the part of the partici pant, site inv estigator, 
or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have 
significant effect on the participant ‚Äôs safety, rights, or welfare and/or on th e integrity of the study 
data. Major protocol deviations  must be sent to the study IRB and l ocal IRB per their guidelines, 
recorded in s ource documents, and r eported to the coordinating center. Major protocol deviations 
will be tracked . For this study, any missed or delayed survey completion will not be considered a 
major protocol deviation. Refer to the MOP for details.  
12.4. Publication and Data Sharing Policy  
This study will comply with the NIH Public  Access Policy, which  ensures that the public has 
access to the results of NIH-funded res earch. Methods of data sharing will include 1) archiving 
de-identified data in a data repository and 2) sharing of limited datasets under a Data Use 
Agreement (DUA) and IRB approval. Data will be made avai lable to qualified investigators by 
archiving a fully de -identified dataset in  a platform to be determined at the end of the trial . Both 
repositories allow users to search, view study information, and then submit an application to 
receive data. Prior to ar chiving study data, the DCC will produce a final dataset that will be 
stripped of all personal health information (PHI), including full date elements, in compliance  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 52 with the HIPAA privacy rule. The relative timing of an event will be retained in the dataset 
converting t o study days instead of dates.  
The study result will be returned , including some participant specific results, to enh ance value from 
participation. Study results will be  dissemin ated to the public and the medical community through 
presentations at scientific meetings and publishing manuscripts in high impact peer -reviewed 
journals. The International Committee of Medical Journal Editors (IC MJE) member journals have  
adopted a cli nical studies  registration policy as a condition for publication. The ICMJE defines a 
clinical study as  any research project that prosp ectively assigns human participants  to 
intervention or concurrent comparison or control groups to study the cause-and-effect 
relationship between a medical intervention and a health outcome. The ICMJE  policy, and  the 
Section 801 of the Food and Drug Administration Amendments Act of 2007, req uires that all 
clinical studies be regi stered in  a public registry such as ClinicalTrials .gov, which is spons ored 
by the Nat ional Library of Medicine. For interventional cli nical trials per formed under NIH IC 
grants and cooperative agreements, it is the gra ntee‚Äôs responsibility to register the study in an  
acceptable registry, so the research results  may be considered f or publication in ICMJE  member 
journals.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 53 13. Study Leadership  
The Steering Committee is a multi -stakeholder committee that oversees the study and includes 
representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation 
Warp Speed, the FDA , National Center for Advancing Translational Scie nces (NCATS), ACTIV 
representatives with no conflict of interest, and academic and industry advocates .  
The CCC  and DCC  are ea ch overseen  by principal investigator(s). The CCC  is responsible for 
study coordination, site management, communication, and finan cial administrat ion. The DCC  is 
responsible for treatment allocations, receipt and processing of data, quality control programs, 
and statistical analysis and reporting.   
An independent IDMC  will oversee the safety and welfare of trial participants as well  as provide 
recommendations for continuation, discontinuation or revision of the trial.  
 
 
Figure 2: Operational Structure Diagram  

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 54 14. Summary of Changes  
Protocol Version (version #, date)  Summary of Changes  
Version 1.0, 01APR 2021 N/A, Version 1.0  
Version 2.0, 25MAY2021  ÔÇ∑ Added current use of study drug or 
study drug/device combination as an 
exclusion criteria (Sections 1.1 and 
5.2); 
ÔÇ∑ Added a  phone call follow -up the day 
after first study drug dose , clarified 
that follow -up w ill occur if two 
consecutive days of reporting are 
missed during Days 3 -14, and added 
that sites/call center will collect 
missing survey information during 
follow -up calls (Section 7.3); 
ÔÇ∑ Added at-home pulse oximetry 
readings and description of at -home 
pulse oximetry reading collection 
(Table 1 and Section 8.2); 
ÔÇ∑ Added symptom severity scale 
(Section 8.2); 
ÔÇ∑ Added Adverse Device Effect and 
Unanticipated Adverse Device Effects 
definitions, collection/reporting period 
details, and causality assessment 
details (Sections 9.1.1 , 9.1.2 , 9.1.3 , 
9.1.4 ); 
ÔÇ∑ Clarified that hypoxia ESI will only be 
collected from hospitalized 
participants (Section 9.1.5 ); 
ÔÇ∑ Clarified that any missing or delayed 
survey completion will not be 
considered a major protocol deviation 
(Section 12.3); 
ÔÇ∑ Updated Ivermectin and matched 
placebo information and packaging 
(Sections 16.3, 16.3.1 , 16.3.3 , 16.4.1 ); 
ÔÇ∑ Added Appendix B ‚Äì Fluvoxamine 
maleate (Section 17); 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 55 ÔÇ∑ Added Appendix C ‚Äì Fluticasone 
Furoate (Section 18); 
ÔÇ∑ Changed symptom freedom to 
symptom resolution for consistency 
throughout;  
ÔÇ∑ Other administrative changes 
throughout.  
Version 3.0, 06JUL 2021 ÔÇ∑ Clarified that the sample size increase 
will included 1:1 active study drug to 
placebo (Section 1.1); 
ÔÇ∑ Added footnote 6 to COVID -19 
Outcomes during Intervention Period 
to clarify that these will be assessed on 
Day 7 and 14 ( Table 1); 
ÔÇ∑ Added that events that are COVID -19 
related AND study drug related and 
unexpected will be considered 
reportable (Section 9.1.4 ); 
ÔÇ∑ Updates made to fluvoxamine 
appendix: excluded linezolid , use of 
fluoxetine within 45 days of consent, 
and bipolar disorder  per FDA 
feedback (Section 17.2); added 
precautions of additional drugs 
including t ramadol, buspirone, 
fentanyl, lithium, a mphetamines, St. 
John‚Äôs Wart,  carbamazepine, 
quinidine, and tacrine  per FDA 
feedback (Section 17.2.1 ); 
ÔÇ∑ Updates made to fluticasone furoate 
appendix: brand name Arnuity Ellipta 
replaced with fluticasone furoate 
throughout (Section 18); changed liver 
failure exclusion criteria to ‚Äúmoderate 
to severe hepatic impairment, defined 
as Child -Pugh B or C ‚Äù (Section 18.2); 
remo ved hepatic impairment 
precautions as it was added to 
exclusion criteria (Section 18.2.1 ); 
ÔÇ∑ Other minor administrative changes 
throughout . 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 56 15. References  
1. COVID -19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map -faq.html . 
2. McIntosh, K. Coronavirus disease 2019 . 2020  [cited 2020 March 24].  
3. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 ‚Äî Final Report.  New 
England Journal of Medicine, 2020. 383(19): p. 1813 -1826.  
4. Dexamethasone in Hospitalized Patients with Covid -19 ‚Äî Preliminary Report.  New 
England Journal of Medicine, 2020.  
5. Gordon, A.C., et al., Interleukin -6 Receptor Antagonists in Critically Ill Patients with 
Covid -19 ‚Äì Preliminary report.  medRxiv, 2021: p. 2021.01.07.21249390.  
6. Baden, L.R., et al., Efficacy and Safety of the mRNA -1273 SARS -CoV-2 Vaccine.  New 
England Journal of Medicine, 2020. 384(5): p. 403 -416. 
7. Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid -19 Vaccine.  New 
England Journal of Medicine, 2020. 383(27): p. 2603 -2615.  
8. Voysey, M., et al., Safety and efficacy of the ChAdOx1 nCoV -19 vaccine (AZD1222) 
against SARS -CoV-2: an interim analysis of four randomised controlled trials in Brazil, 
South Africa, and the UK.  The Lancet, 2021. 397(10269): p. 99 -111. 
9. Wang, Z., et al., mRNA vaccine -elicited antibodies to SARS -CoV-2 and circulating 
variants.  bioRxiv, 2021: p. 2021.01.15.426911.  
10. Grein, J., et al., Compassionate Use of Remdesivir for Patients with Severe Covid -19. 
New England Journal of Medicine, 2020. 382(24): p. 2327 -2336.  
11. Beigel, J.H., et al., Remdesivir for  the Treatment of Covid -19 ‚Äî Preliminary Report.  New 
England Journal of Medicine, 2020.  
12. McCreary, E.K., J.M. Pogue, and o.b.o.t.S.o.I.D. Pharmacists, COVID -19 Treatment: A 
Review of Early and Emerging Options.  Open Forum Infectious Diseases, 2020.  
13. Kalil, A.C., Treating COVID -19‚ÄîOff-Label Drug Use, Compassionate Use, and 
Randomized Clinical Trials During Pandemics.  JAMA, 2020.  
14. Wyatt, M.A., et al., Implementation of the ‚ÄúPregnancy Reasonably Excluded Guide‚Äù for 
Pregnancy Assessment: A Quality Init iative in Outpatient Gynecologic Surgery.  
Obstetrics & Gynecology, 2018. 132(5): p. 1222 -1228.  
15. Print, W.H.O.R.D.B. Novel Coronavirus COVID -19 Therapeutic Trial Synopsis . 2020.  
16. Cella, D., et al., The Patient -Reported Outcomes Measurement Information  System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years.  
Med Care, 2007. 45(5 Suppl 1): p. S3 -S11. 
17. Hays, R.D., et al., PROMIS(¬Æ) -29 v2.0 profile physical and mental health summary 
scores.  Quality of life research : an international journal of quality of life aspects of 
treatment, care and rehabilitation, 2018. 27(7): p. 1885 -1891.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 57 18. Whitehead, J., Sample size calculations for ordered categorical data.  Stat Med, 1993. 
12(24): p. 2257 -71. 
19. Boussinesq, M., et al., Clinical picture, epidemiology and outcome of Loa -associated 
serious adverse events related to mass ivermectin treatment of onchocerciasis in 
Cameroon.  Filaria journal, 2003. 2 Suppl 1 (Suppl 1): p. S4 -S4. 
20. Makenga Bof, J.C., et al., Onchocerciasis control in the Democratic Republic of Congo 
(DRC): challenges in a post -war environment.  Trop Med Int Health, 2015. 20(1): p. 48 -
62. 
21. Chandler, R.E., Serious Neurological Adverse Events after Ivermectin -Do They Occur 
beyond the Indication of Onchocerciasis?  Am J Trop Med Hyg, 2018. 98(2): p. 382 -388. 
22. Barkwell, R. and S. Shields, Deaths associated with ivermectin treatment of scabies.  
Lancet, 1997. 349(9059): p. 1144 -5. 
23. MERCK & CO., I. TABLETS STROMECTOL (R) (IVERMECTIN) Product Label . 2009  
[cited 2021 F ebruary 12]; Available from: 
file:///U:/Personal/My%20Documents/Medical%20Writing/COVID/ACTIV -
6/Study%20Drugs/Ivermectin.pdf.  
24. Nicolas, P., et al., Safety of oral ivermectin during pregnancy: a systematic review and 
meta -analysis.  The Lancet Global Heal th, 2020. 8(1): p. e92 -e100.  
25. Pacqu√©, M., et al., Pregnancy outcome after inadvertent ivermectin treatment during 
community -based distribution.  The Lancet, 1990. 336(8729): p. 1486 -1489.  
26. Addiss, D.G., et al., Randomised placebo -controlled comparison  of ivermectin and 
albendazole alone and in combination for <em>Wuchereria bancrofti</em> 
microfilaraemia in Haitian children.  The Lancet, 1997. 350(9076): p. 480 -484. 
27. Dreyer, G., et al., Treatment of bancroftian filariasis in Recife, Brazil: a two -year 
comparative study of the efficacy of single treatments with ivermectin or 
diethylcarbamazine.  Trans R Soc Trop Med Hyg, 1995. 89(1): p. 98 -102. 
28. Heukelbach, J., S. Franck, and H. Feldmeier, Therapy of tungiasis: a double -blinded 
randomized controlled trial with oral ivermectin.  Mem Inst Oswaldo Cruz, 2004. 99(8): 
p. 873 -6. 
29. Martin -Prevel, Y., et al., Tolerance and efficacy of single high -dose ivermectin for the 
treatment of loiasis.  Am J Trop Med Hyg, 1993. 48(2): p. 186 -92. 
30. Smit, M.R., et al., Safety and mosquitocidal efficacy of high -dose ivermectin when co -
administered with dihydroartemisinin -piperaquine in Kenyan adults with uncomplicated 
malaria (IVERMAL): a randomised, double -blind, placebo -controlled trial.  Lancet Infect 
Dis, 2018. 18(6): p. 615 -626. 
31. LLC, E.P., Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure . 2021.  
32. Yang, S.N.Y., et al., The broad spectrum antiviral ivermectin targets the host nuclear 
transport importin Œ±/Œ≤1 heterodimer.  Antiviral Res, 2020. 177: p. 104760.  
33. Caly, L., et al., The FDA -approved drug ivermectin inhibits the replication of SARS -CoV-
2 in vitro.  Antiviral Research, 2020. 178: p. 104787.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 58 34. Lehrer, S. and P.H. Rheinstein, Ivermectin Docks to the SARS -CoV-2 Spike Receptor -
binding Domain Attached  to ACE2.  In Vivo, 2020. 34(5): p. 3023 -3026.  
35. Guzzo, C.A., et al., Safety, tolerability, and pharmacokinetics of escalating high doses of 
ivermectin in healthy adult subjects.  Journal of clinical pharmacology, 2002. 42(10): p. 
1122-1133.  
36. Chaccour, C., et al., Ivermectin and COVID -19: Keeping Rigor in Times of Urgency.  Am 
J Trop Med Hyg, 2020. 102(6): p. 1156 -1157.  
37. Arshad, U., et al., Prioritization of Anti -SARS -Cov-2 Drug Repurposing Opportunities 
Based on Plasma and Target Site Concentrations D erived from their Established Human 
Pharmacokinetics.  Clin Pharmacol Ther, 2020. 108(4): p. 775 -790. 
38. Bray, M., et al., Ivermectin and COVID -19: A report in Antiviral Research, widespread 
interest, an FDA warning, two letters to the editor and the authors' responses.  Antiviral 
research, 2020. 178: p. 104805 -104805.  
39. Zhang, X., et al., Ivermectin inhibits LPS -induced production of inflammatory cytokines 
and improves LPS -induced survival in mice.  Inflamm Res, 2008. 57(11): p. 524 -9. 
40. Ci, X., et al., Avermectin exerts anti -inflammatory effect by downregulating the nuclear 
transcription factor kappa -B and mitogen -activated protein kinase activation pathway.  
Fundam Clin Pharmacol, 2009. 23(4): p. 449 -55. 
41. DiNicolantonio, J.J., J. Barroso -Arranda,  and M. McCarty, Ivermectin may be a clinically 
useful anti -inflammatory agent for late -stage COVID -19. Open Heart, 2020. 7(2): p. 
e001350.  
42. Ahmed, S., et al., A five -day course of ivermectin for the treatment of COVID -19 may 
reduce the duration of illn ess. Int J Infect Dis, 2021. 103: p. 214 -216. 
43. Chachar, A.Z.K., et al., Effectiveness of Ivermectin in SARS -CoV-2/COVID -19 Patients.  
International Journal of Sciences, 2021.  
44. Abu Taiub Mohammed Mohiuddin, C., et al., Research Square, 2021.  
45. Soto-Becerra, P., et al., Real-World Effectiveness of Hydroxychloroquine, Azithromycin, 
and Ivermectin Among Hospitalized COVID -19 Patients: Results of a Target Trial 
Emulation Using Observational Data from a Nationwide Healthcare System in Peru.  
SSRN Electronic  Journal, 2020.  
46. Hashim, H.A., et al., Controlled randomized clinical trial on using Ivermectin with 
Doxycycline for treating COVID -19 patients in Baghdad, Iraq.  medRxiv, 2020: p. 
2020.10.26.20219345.  
47. Ahmed, E., et al., Research Square, 2021.  
48. Khan, M.S.I., et al., Ivermectin Treatment May Improve the Prognosis of Patients With 
COVID -19. Arch Bronconeumol, 2020. 56(12): p. 828 -830. 
49. Morgenstern, J., et al., The use of compassionate Ivermectin in the management of 
symptomatic outpatients and hos pitalized patients with clinical diagnosis of COVID -19 at 
the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 59 Dominican Republic, from may 1 to august 10, 2020.  medRxiv, 2020: p. 
2020.10.29.20222505.  
50. Krolewiecki, A., et al., Antiviral Effect of High -Dose Ivermectin in Adults with COVID -
19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial . 2020, SSRN.  
51. Podder, C.S., et al., Outcome of ivermectin treated mild to moderate COVID -19 cases: a 
single -centre, open -label , randomised controlled study.  IMC Journal of Medical Science, 
2020. 14(2). 
52. Ravikirti, et al., Ivermectin as a potential treatment for mild to moderate COVID -19 ‚Äì A 
double blind randomized placebo -controlled trial.  medRxiv, 2021: p. 
2021.01.05.21249310 . 
53. Morteza Shakhsi, N., et al., Research Square, 2021.  
54. Espitia -Hernandez, G., et al., Effects of Ivermectin -azithromycin -cholecalciferol 
combined therapy on COVID -19 infected patients: A proof of concept study.  Biomedical 
Research, 2020.  
55. Babalol a, O., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: A 
randomised controlled double blind dose response study in Lagos.  medRxiv, 2021: p. 
2021.01.05.21249131.  
56. NIH. COVID -19 Treatment Guidelines Fluvoxamine . 2021  [cited 2021 A pril 23]; 
Available from: 
https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/ . 
57. Apotex, Higlights of Fluvoxamine Maleate Tablets Prescr ibing Information . 
58. Lenze, E.J., et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients 
With Symptomatic COVID -19: A Randomized Clinical Trial.  JAMA, 2020. 324(22): p. 
2292-2300.  
59. Rosen, D.A., et al., Modulation of the sigma -1 recep tor‚ÄìIRE1 pathway is beneficial in 
preclinical models of inflammation and sepsis.  Science Translational Medicine, 2019. 
11(478): p. eaau5266.  
60. Rafiee, L., V. Hajhashemi, and S.H. Javanmard, Fluvoxamine inhibits some inflammatory 
genes expression in LPS/s timulated human endothelial cells, U937 macrophages, and 
carrageenan -induced paw edema in rat.  Iran J Basic Med Sci, 2016. 19(9): p. 977 -984. 
61. Seftel, D. and D.R. Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of 
Coronavirus Disease 19.  Open Forum Infectious Diseases, 2021. 8(2). 
62. GlaxoSmithKline, Highlights of Prescribing Information for Arnuity Ellipta . 2018: 
Online.  
63. Yamaya, M., et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on 
coronavirus HCoV -229E replication and cytokine production by primary cultures of 
human nasal and tracheal epithelial cells.  Respir Investig, 2020. 58(3): p. 155 -168. 
64. Peters, M.C., et al., COVID -19-related Genes in Sputum Cells in Asthma. Relationship to 
Demographic Features  and Corticosteroids.  Am J Respir Crit Care Med, 2020. 202(1): p. 
83-90. 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 60 65. Finney, L.J., et al., Inhaled corticosteroids downregulate the SARS -CoV-2 receptor ACE2 
in COPD through suppression of type I interferon.  J Allergy Clin Immunol, 2021. 147(2): 
p. 510-519.e5.  
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 61 16. Appendix A ‚Äì Ivermectin  
16.1. Risk Assessment  
The most commonly reported adverse events for ivermectin are pruritus (25.3%), headache 
(13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of 
ivermectin in humans for the treatment of filariasis, especially onchocerciasis, ha s been 
associated with SAEs, including coma, seizure and death only when administered in regions 
where onchocerciasis  and loiasis  are co -endemic . [19] 
The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the 
control and elimination of disease  in communities co -endemic with  O. volvulus  and Loa loa . 
Mass drug administration  were suspended from 2004 to 2006 in some health zones in the 
Equateur, Bas Congo, and Oriental provinces in the D emocratic Republic of the Congo because 
of ivermectin -associated SAEs in the Bas Congo and Oriental p rovinces in 2003 . [20] It has been 
thought that c o-infection with L. loa  is a risk factor for the development of these reactions.  [21] 
Additionally, a study investigating escalating high doses of ivermectin in healthy adults was 
performed to explore the safety of its use in the treatmen t of head lice. The authors documented 
no evidence of CNS toxicity in doses up to 10 times the highest FDA -approved dose of 200 
¬µg/kg.  [22] 
Table 3 shows safety events that occurred in greater than 5% of the clinical trial population  who 
received ‚â• 300 ¬µg/kg of ivermectin . [23]  For a detailed list of the adverse reactions t hat occurred 
during clinical trials with ivermectin, refer to the product label  and the Investigator‚Äôs Brochure . 
Ivermectin is pregnancy category C and is not contraindicated per FDA. Analyses of outcomes 
of pregnancies in women inadvertently exposed to ivermectin through mass administration 
campaigns show no evidence of increased birth defects, neonatal deaths, maternal morbidity, 
preterm births, or low birthweight over baseline rates. [24, 25]  
Table 3: Ivermectin Adverse Event Table  for Doses ‚â• 300 ¬µg/kg 
Indication (dose)  
Wuchererua bancrofti  
(200 -400 ¬µg/kg)  [26] 
Wuchererua bancrofti  
(200 ¬µg/kg, then 400 
¬µg/kg on day 4)  [27] 
Stage II or III tungiasis 
lesions (300 ¬µg/kg, 
days 1 & 2)  [28]  
Loa loa  infection (300 
or 400 ¬µg/kg)  [29] 
Symptomatic 
Plasmodium 
falciparum  malaria 
(600 ¬µg/kg)  [30] 
Advers e Reaction s 
Abdominal Pain    7%   
Cough  42%     
Diarrhea     6.5%   
Eye disorders      9% 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 62 Fever  69% 46%  8%  
Gastrointestinal   18%    
Headache  75%  11% 16%  
Local Inflammation   9%    
Local Pain   9%    
Lumber myalgia     6.5%   
Malaise   27%    
Myalgia  37%     
Neurological   15%    
Pneumonia      9% 
Pruritus     60%  
Renal   33%    
Respiratory   33%    
16.2. Additional Appendix -Level Exclusion Criteria  
1. End-stage renal disease on renal replacement therapy  
2. Liver failure  or decompensated cirrhosis  
3. Use of warfarin , CYP3A4, P -gp inhibitor drugs, or CYP3A4 substrates  (see Section 
16.2.1 ) 
4. Nursing mothers  
5. Pregnancy*   
*Participants must agree to use a n effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine 
device,  progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
16.2.1.  Precautions  
While rare, post -marketing reports indicate an increased International Normalized Ratio (INR) 
when ivermectin was co -administered with warfarin.  With a 3 -day dosing period this is unlikely 
to be a significant issue , but INR monitoring can be recommended to the care provider if felt 
warranted by site investigator .   
Use of CYP3A4  inducers and inhibitors and  P-gp inhibitor are contraindicated for use with 
ivermectin.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 63 16.3. Ivermectin  Information  
Ivermectin is a semisynthetic oral agent used primarily as an anti -parasitic agent. It  is derived 
from highly active, broad -spectrum, anti -parasitic agents isolated from Streptomyces avermitilis  
fermentation products.  It binds selectively, and with high affinity, to glutamate -gated chloride 
ion channels, therefore increasing cell membrane permeability to chloride ions resulting in death 
of the parasite.  [31] It is currently FDA -approved for the following indications: st rongyloidiasis 
of the intestinal tract due to the nematode parasite Strongyl oides stercoralis  and onchocerciasis 
due to the nematode parasite Onchocerca volvulus . [23] Per the FDA -approved labelling of 
ivermectin, the recommended dose is 200 ¬µg/kg/day to treat strongyloidiases and 150 ¬µg/kg/day 
to treat onchocerciasis in the form of a 3 mg tablet.    
16.3.1.  Formulation, Appearance, Packaging, and Labeling  
Ivermectin is a white to yellowish -white, nonhygroscopic, crystalline powder. For this study, 
ivermectin will be supplied as fifteen 7-mg tablets in a bottle  with a single panel label . The 
tablets are white, round, biconvex tablets with ‚Äú123‚Äù over the scoring on one side. All packaging 
will be labeled to indicate that the product is for investigational use.  
16.3.2.  Drug Dispensing, Storage, and Stability  
Ivermectin will be supplied as 7 -mg tablets and must be stored at temperatures below 30 ¬∞C. 
16.3.3.  Dosing and Administration  
Ivermectin should be taken on an empty stomach with water  (30 minutes before a meal or 2 
hours after a meal). Each participant will receive  a bottle of fifteen  7-mg tablets and will be 
instructed to take a pre -specified number of tablets for 3 consecutive  days based on their weight 
(see Table 4) for a daily dose of approximately 300-400 ¬µg/kg . 
Table 4: Ivermectin Dosing Schedule  
Weight (kg)  Day 1 (# of 7 -
mg tablets)  Day 2 (# of 7 -
mg tablets)  Day 3 (# of 7 -
mg tablets)  Daily Dose  
(¬µg/kg)  
35-52 2 2 2 269-400 
53-69 3 3 3 304 -396 
70-89 4 4 4 315-400 
>90 5 5 5 ‚â§389 
16.3.4.  Rationale for Selection of Dose  
Pre-clinical studies:  
Reports from in vitro  studies suggest that ivermectin acts against RNA viruses such as SARS -
CoV-2 by inhibiting the host importin Œ±/Œ≤ -mediated nuclear transport that prevent viral proteins 
from entering the nucleus to alter host cell function.  [32] A single dose additio n of ivermectin to 
Vero -hSLAM cells 2 hours post infection with SARS -CoV-2 was able to effect a 5000 -fold 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 64 reduction in viral RNA at 48 hours  and may interfere with the att achment of SARS -CoV-2 spike 
protein to the human cell membrane.  [33, 34]  
Ivermectin has been shown to inhibit the replication of SARS -CoV-2 in cell culture. However, 
pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100 -fold 
higher than those approved for use in humans would b e required to achieve the plasma 
concentrations necessary to duplicate the drug‚Äôs antiviral efficacy in vitro . [35, 36]  Even though 
ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, 
predicted systemic plasma and lung tissue concentrations are much lower than 2 ¬µM, the half -
maximal inhibitory concentration (IC 50) against SARS -CoV-2 in vitro . [37, 38]  
Ivermectin demonstrates potential anti -inflammatory properties in some in vitro  
studies,  properties which have been postulated to be beneficial in the treatment of COVID -19. 
[39-41] The dose range for an anti -inflammatory effect may be lower than for the anti -viral 
effects.  [41]   
Clinical studies:  
A number of retrospective cohort studies and the results of several randomized trials of 
ivermectin use in patients with COVID -19 have been published in peer -reviewed journals  or 
made available as preliminary, non -peer-reviewed reports. Some clinical studies showed no 
benefits after ivermectin use, whereas others reported shorter time to resolution of disease 
manifestations attributed to COVID -19, greater reduction in inflammat ory markers,  shorter time 
to viral clearance,  or lower mortality rates in patients who received ivermectin than in patients 
who received comparator drugs or placebo.  [42-48] 
Most of the studies reported to date are limited by their small sample size, varying dosing 
schedules and the adjunctive use of various concomitant medication s (e.g., doxycycline, 
hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true 
efficacy or safety of ivermectin.  Clinical studies in outpatients with COVID -19 did not always 
describe the severity of COVID -19 and the stud y outcome measures were not always defined. 
Nonetheless, while some have shown no difference, most clinical trials of outpa tients with 
mild/moderate COVID -19 have shown clinical improvement with even a single dose or a short 
two to five -day cours e of ivermectin given orally shortly after symptom onset.  [36, 46, 49, 50]   
There is a dose -dependent relationship between i vermectin dos e and clinical efficacy. Trials 
using lower doses of i vermectin  tend to show no or minimal clinical benefit in COVID -19 
patients treated in the outpatient or h ospital setting.  [51, 52]  Higher doses, at least 0.4  mg/kg, 
particularly when administered in multiple doses , have been shown to significantly reduce time 
to recovery and mortality as compared with lower  doses or placebo/standard care . [49, 53 -55] 
There is a concentration -dependent virologic response seen using higher -than-usual doses of 
ivermectin (600 Œºg/kg vs. 200  Œºg/kg once daily for 5 days)  that have been shown to significantly 
reduce the time to PCR viral positivity over standard doses with minimal associated toxicities.  
[50]  
The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested  
in healthy adult subjects . [35] Doses from 30 mg/day (347 -571 ¬µg/kg)  to 120 mg/day  (1404 -
2000 ¬µg/kg) given for 3 days were all well tolerated . [35] These data  coupled with evidence of 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 65 superior clinical efficacy of doses in the lower of this range provide the rationale for the 300 -400 
¬µg/kg dose given f or 3 days in the proposed trial.  
16.4. Placebo Information  
16.4.1.  Formulation, Appearance, Packaging, and Labeling  
Placebo will match the appearance of  the 7-mg ivermectin tablets: white, round, biconvex tablets 
with ‚Äú123‚Äù over the scoring  on one side . A total of fifteen  tablets will be  provided in a  bottle  
with a single panel label . The placebo formulation includes the following ingredients in a 210 mg 
tablet: microcrystalline cellulose, NF (MC-102; pregelatinized s tarch, NF  (Starch 1500) ; 
croscarmellose s odium, NF  (Vivasol, GF Grade) ; colloidal silicon d ioxide, NF  (Aerosil 200)  and 
magnesium s tearate, NF (2257) . All packaging will be labeled to indicate that the product is for 
investigational use.  
16.4.2.  Drug Dispensing, Storage, and Stability  
Placebo must be stored at temperatures below 30¬∞C.  
16.4.3.  Dosing and Administration  
Dosing and administra tion will occur according to Section 16.3.3  in order to maintain blinding.  
16.5. Events of Special Interest  
None  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 66 17. Appendix B ‚Äì Fluvoxamine Maleate  
17.1. Risk Assessment  
The most common adverse effects of fluvoxamine described in the setting of  treatment of 
psychiatric conditions include gastrointestinal effects, neurological effects, dermatological 
reactions, and in rare cases suicidal ideation.  [56] In two 10 -week controlled trials in Obsessive 
Compulsive Disorder (OCD) and depression at  doses ranging from 100 -300 mg/day, the most 
commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets 
(incidence of 5% or greater and at least twice that for placebo) were nausea, somnolence, 
insomnia, asthenia, nervousnes s, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, 
and vomiting  (see Table 5). [57]   
Table  6 lists the complete set of adverse events identified in a randomized clinical trial of 
fluvoxamine (300 mg/day for 15 days) versus placebo in 152 COVID -19 participants. [58] 
Adverse events and serious adverse events were more common in the placebo arm and the single 
SAE in the fluvoxamine  arm was dehydration and the study medication was not interrupted.  [58]  
Table 5. Fluvoxamine Adverse events occur ring in 10 -week studies of adult OCD or 
depression  
 *Table shows events that  occurred in ‚â• 5% of adult OCD and depression  study  
participants rec eiving 100 -300 mg/day for 10 weeks of fluvoxamine maleate versus 
placebo. [57] 
Adverse Reaction  Fluvoxamine, 
n=892 (%)  Placebo, 
n=778 (%)  
Headache  22 20 
Asthenia  14 6 
Nausea  40 14 
Diarrhea  11 7 
Constipation  10 8 
Dyspepsia  10 5 
Anorexia  6 2 
Vomiting  5 2 
Somnolence  22 8 
Insomnia  21 10 
Dry Mouth  14 10 
Nervousness  12 5 
Dizziness  11 6 
Tremor  5 1 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 67 Anxiety  5 3 
 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants 
receiving 300 mg/day for 15  days.  
Adverse Reaction  [58] 
 Fluvoxamine, n=8 0 
(%) Placebo, n=72  
(%) 
Pneumonia  3.8 8.3 
Shortness of breath  2.5 5.6 
Headache or head pain  2.5 1.4 
Gastroenteritis, nausea, or vomiting  1.3 6.9 
Muscle aches  1.3 0 
Bacterial infection  1.3 0 
Vasovagal syncope  1.3 0 
Teeth chattering  1.3 0 
Dehydration  1.3 0 
Low oxygen saturation or hypoxia  0 8.3 
Chest pain or tightness  0 2.8 
Fever  0 2.8 
Acute respiratory failure  0 1.4 
Serious adverse events  1.3 6.9 
Other adverse events  13.8 8.3 
17.2. Additional Appendix -Level Exclusion Criteria  
1. Use of selective serotonin  (or norepinephrine)  reuptake inhibitors (SSRIs/SNRIs) , 
including fluvoxamine,  or monoamine oxidase inhibitors (MAOIs) within 2 
weeks of consent including triptans and tryptophan . Use of fluoxetine within 45 
days of consent.   
2. Co-administration of tizanidine, thioridazine, alosetron, pimozide, diazepam, 
ramelteon , linezolid  
3. Bipolar D isorder  
4. Nursing mothers  
5. Pregnancy*  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 68 *Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tub al ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
17.2.1.  Precaution s 
Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 
2D6, and 3A4, as such, it may enhance anticoagulant effects of antiplatelets and anticoagulants 
as well as other medications. It is recommended that concomitant medications listed below be 
discussed with participants and potential effects of increased drug exposure reviewed and 
monitored by th e participant and/or their prescribing clinician.  
ÔÇ∑ Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, 
imipramine  
ÔÇ∑ Antipsychotic drugs: neuroleptic malignant syndrome or similar; particularly 
clozapine (hypotension, seizure)  
ÔÇ∑ Benzodiazepines: particularly alprazolam; recommend dose reduction  
ÔÇ∑ Tramadol, buspirone, fentanyl, lithium, amphetamines, St. John‚Äôs Wart , 
carbamazepine , quinidine,  and tacrine  
ÔÇ∑ Methadone: opioid intoxication  
ÔÇ∑ Mexiletine: monitor for side effects  
ÔÇ∑ Theophylli ne: recommend dose reduction and monitor for side effects  
ÔÇ∑ Warfarin: monitor INR  
ÔÇ∑ NSAIDS or aspirin: monitor for signs of bleeding  
ÔÇ∑ Diltiazem, propranolol, metoprolol: monitor for bradycardia  
Participants should be warned about fluvoxamine inhibition of caffe ine metabolism. A 
description is 1 cup of coffee has the effects of 4 cups  while taking fluvoxamine .  
Caution should be used in participants with hepatic dysfunction due to approximately 30% 
increase in exposures .  
17.3. Fluvoxamine  Information  
Fluvoxamine is an FDA -approved SSRI for the treatment of OCD . Clinically it is also used for 
other conditions such as depression. [56] The active ingredient in fluvoxamine is fluvoxamine 
maleate.  
17.3.1.  Formulation, Appearance, Packaging, and Labeling  
Fluvo xamine is a round golden 50 mg tablet that is scored on both sides - one side has ‚ÄúAPO‚Äù 
and the other side has ‚ÄúF50‚Äù with a partial bisect. All packaging will be labeled to indicate that 
the product is for investigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 69 17.3.2.  Drug Dispensing, Storage, and  Stability  
Drug will be supplied by Apotex and distributed by Belmar Pharmacy. Study drug should be 
stored in controlled room temperature (20 ¬∞C to 25¬∞C) ; excursions are permitted to 15 ¬∞C to 30 ¬∞C. 
17.3.3.  Dosing and Administration  
Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg BID for 10 
days.  
17.3.4.  Rationale for Selection of Dose  
The recommended starting dose of fluvoxamine for OCD  in adults is 50 mg daily dose to be 
titrated up to a maximum of 300 mg/day divided into BI D doses. Clinical data from the placebo -
controlled, randomized trial in nonhospitalized adults with mild COVID -19 demonstrated that a 
50 mg BID fluvoxamine dose was well -tolerated and effective (see Figure 4).[58] In the same 
study, doses of 100 mg BID in COVID -19 participants resulted in additional side effects  over a 
14-day period . The 300  mg daily dose i s for serotonin receptor activity, whereas the postulated 
dose for sigma -1 receptor activity as an anti -inflammatory is lower.  Therefore, the proposed 
dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dose to 
maximize effic acy and minimize toxicity.  
Pre-Clinical Studies : 
Pre-clinical studies have indicated that the anti -inflammatory effects of fluvoxamine may support 
its use for treating COVID -19. Systemic inflammation as a result of infection can damage 
vasculature which ma y lead to tissue hypoperfusion and multiple organ failure. [59] Reducing 
systemic inflammation thereby  may avoid  or mitigate  the aforementioned serious clinical 
outcomes. In murine studies, administration of fluvoxamine significantly increased survival of 
S1R wildtype (WT) mice and S1R knockout (KO) mice challe nged with ligand 
lipopolysaccharide (LPS) as compared to mice that received saline ( Figure 3).[59] Fluvoxamine 
also reduced production of inflammator y cytokines in ex vivo  and in vitro  murine and human 
cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow -derived 
macrophages) and inflammatory genes in human endothelial cells. [59, 60]  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 70  
Figure 3: Survival curve of WT and S1R KO mice  
Figure note: Mice were treated with vehicle (33% Kolliphor in saline) or STF (30 mg/kg) after 
administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; **P < 0.01, 
***P < 0.001, log -rank test). [59] 
Clinical Studies : 
A placebo -controlled, randomized trial in nonhospitalized adults with mild COVID -19 tested the 
efficacy and safety of fluvoxamine (50  mg oral one -time dose, followed by 100  mg orally twice 
daily for 2 days, followed by 100  mg orally three t imes daily through day 15) versus placebo  
[58]. Results of the study reported that 8.3% (6/72) of participants who received placebo 
experienced clinical deterioration within 15 days of randomization, as opposed to 0 % (0/80) in 
the fluvoxamine arm (absolute difference 8.7%; 95% CI, 1.8% to 16.5%;  P = 0.009) .[58]  
Clinical deterioration was  defined as shortness of breath /pneumonia with hypoxia  (Figure 4). 
Concomitant SSRI/SNRI dosing was not allowed per the trial protocol thus the participant‚Äôs 
SSRI/SNRI was held for the study dosing period  if reported at baseline .  

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 71  
Figure 4: Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early 
COVID -19.  
A prospective, nonrandomized observational cohort study that evaluated fluvoxamine showed 
that on Day 14, 0/65 participants had persistent symptoms as opposed to 19/48 participants who 
did not receive fluvoxamine (P < 0.001)  [61]. Add itionally, by Day 14, none of the participants 
who received fluvoxamine were hospitalized as compared to 6 participants who were 
hospitalized who did not receive the drug (see Figure 5). In this study, all participants were 
offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to 
receive the study drug received 50 mg of fluvoxamine two time s a day following an upfront 100 
mg loading dose. [61]  
 
Figure 5: Summary of study results for the prospective, nonrandomized observational 
cohort study with fluvoxamine in participants diagnosed with COVID -19.  

CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 72 17.4. Placebo Information  
The placebo will be a fluvoxamine -matched placebo containing mannitol, magnesium stearate, 
hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and purified 
water . The appearance and packaging will match that of the study drug (as described in Section 
17.3.1 ). All packaging will be labeled to indicate that the product is for investigational use .  
17.4.1.  Formulation, Appearance, Pac kaging, and Labeling  
Placebo will match the appearance of the fluvoxamine tablets: round golden 50 mg tablet that is 
scored on both sides - one side has ‚ÄúAPO‚Äù and the other side has ‚ÄúF50‚Äù with a partial bisect. All 
packaging will be labeled to indicate tha t the product is for investigational use.  
17.4.2.  Drug Dispensing, Storage, and Stability  
Placebo  will be supplied by Apotex and distributed by Belmar Pharmacy. Placebo  should be 
stored in controlled room temperature (20¬∞C to 25¬∞C).  
17.4.3.  Dosing and Administration  
Participants  will self-administer  one placebo tablet orally , twice daily for 10 days.  
17.5. Events of Special Interest  
None  
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 73 18. Appendix C ‚ÄìFluticasone Furoate  
18.1. Risk Assessment  
The most common adverse reactions reported in ‚â• 5% of adults and adolescents  with lung 
disease  include nasopharyngitis, bronchitis, upper respiratory tract infection, and headache. 
Long -term use of systemic and local corticosteroid s may also result in the following side effects: 
Candida albicans  infection, immunosuppression, hyper corticism and adrenal suppression, 
reduction in bone mineral density (BMD), or glaucoma and cataracts.  [62] 
There are insufficient data on the use of fluticasone furoate  in pregnant women. There are 
clinical considerations with use of fluticasone furoate  in pregnant women to inform drug-
associated risk  and b enefit . In animal reproduction studies, fluticasone furoate administered by 
inhalation to rats and rabbits during the period of organogenesis produced no fetal structural 
abnormalities. The highest fluticasone furoate doses in the rat and rabbit studies we re 4 times and 
1 times the maximum recommen ded human daily inhalation dose, respectively. The estimated 
risk of major birth defects and miscarriage for the indicated populations is unknown. In the US 
general population, the estimated risk of major birth de fects and miscarriage in clinically 
recognized pregnancies is 2% to 4% and 15% to 20%, respectively.  [62] 
Disease -Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately 
controlled asthma, there is an increased risk of several perinatal outcomes such as pre -eclampsia 
in the mother and  prematurity, low birth weight, and small for gestational age in the neonate.  
[62]  
Table 7. Fluticasone Adverse reactions that occurred in ‚â•3% of adults and adolescents 
with asthma in a 24 -week trial .  
Adverse Reaction  [62] Fluticasone furoate ,  
fluticasone  200 ¬µg, n=119 
(%) Fluticasone furoate , 
fluticasone  100 ¬µg, 
n=119 (%)  
Nasopharyngitis  13 12 
Headache  13 10 
Bronchitis  7 12 
Influenza  7 4 
Upper Respiratory tract infection  6 2 
Sinusitis  4 7 
Oropharyngeal pain  4 3 
Pharyngitis  3 6 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 74 Back pain  3 3 
Dysphonia  3 2 
Oral candidiasis  3 <1 
Procedural pain  3 <1 
Rhinitis  3 <1 
Throat irritation  3 <1 
Abdominal pain  3 0 
Cough  3 0 
18.2. Additional Appendix -Level Exclusion Criteria  
1. Severe hypersensitivity to milk proteins  
2. Currently prescribed or use within 30 days of inhaled or systemic steroids  
3. Moderate to severe hepatic impairment, defined as Child -Pugh B or C  
4. Nursing mothers  
5. Pregnancy*  
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their fi nal dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
18.2.1.  Precautions  
While not contraindicated, the following should be considered while taking fluticasone furoate : 
ÔÇ∑ Strong cytochrome P450 3A4 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin, 
conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saq uinavir, 
telithromycin, troleandomycin, voriconazole) should be used with caution as 
increased systemic corticosteroid adverse effects may occur in combination with 
fluticasone furoate . Generally, due to the limited study drug administration length, 
clinically significant interactions are unlikely.  
ÔÇ∑ Paradoxical Bronchospasm may occur with an immediate increase in wheezing after 
dosing. Fluticasone furoate should be discontinued immediat ely if this occurs.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 75 18.3. Fluticasone Furoate  Information  
Inhaled fluticasone furoate will be provided by GlaxoSmithKline. It is a synthetic trifluorinated 
inhaled corticosteroid ( ICS) with anti -inflammatory activity. In vitro  and in vivo  models have 
shown th at fluticasone furoate demonstrates anti -inflammatory actions by activating the 
glucocorticoid response element, inhibiting pre -inflammatory transcription factors such as 
NFkB, and inhibiting antigen -induced lung eosinophilia, which may contribute to its e fficacy in 
the approved indications. It is FDA -approved for once -daily maintenance treatment of asthma as 
prophylactic therapy in patients 5 years and older.  [62]  
18.3.1.  Formulation, Appearance, Packaging, and Labeling  
Fluticasone furoate is an inhaled powder drug product. It is a synthetic trifluorinated 
corticos teroid that is insoluble in water. Fluticasone furoate is a white powder. Fluticasone 
furoate  will be provided in a two tone gr ey inhaler with a  mouthpiece cover and separate foil 
blister strips. The blister strips used for this study will contain a white powder mix with a 
mixture of 200 ¬µg micronized fluticasone furoate and lactose monohydrate. The inhaler will be 
packaged in a moisture -protectiv e foil tray with a desiccant and a peelable lid.  [62] All 
packaging will be labeled to indicate that the product is for investigational use.  
18.3.2.  Drug Dispensing, Storage, and Stability  
The study drug should be stored at room temperature (20¬∞C  to 25¬∞C) with excursions permitted 
from 15¬∞C to 30¬∞C. It should be sto red in a dry environment away from direct heat or sunlight. 
Unopened fluticasone furoate should be stored inside the unopened moisture -protective foil tray 
and only removed immediately before use. Any unused study product should be discarded 6 
weeks after opening the foil tray or when the counter reads ‚Äú0‚Äù (after all blisters have been used), 
whichever comes first. The inhaler is not reusable .[62] The study product has a shelf life of 24 
months when stored at ‚â§ 25 ¬∞C. After removal of the secondary package and the desiccant packet 
from the inhaler, the product  may be stored up to 6 weeks at ‚â§ 25 ¬∞C.  
18.3.3.  Dosing and Administration  
Fluticasone furoate is a self -administered inhaled drug. Participants will self -administer 200 ¬µg 
(1 blister) of fluticasone furoate once daily for 14 days. After inhaler activation, the po wder 
within the blister is exposed and the participant inhales the study drug through the mouthpiece.  
18.3.4.  Rationale for Selection of Dose  
Inhaled corticosteroids (ICS) have been shown to be effective in improving asthma and as a 
combination therapy in chronic  obstructive pulmonary disease (COPD) and thus are commonly 
prescribed medications world -wide. Corticosteroids have been shown to have a broad range of 
pharmacologic activity on multiple cell types including mast cells, eosinophils, neutrophils, 
macrophage s and lymphocytes, as well as other mediators of inflammation such as histamine, 
eicosanoids, and leukotrienes. In addition to the anti -inflammatory role of ICS, there is also 
potential for regulation of gene transcription in epithelial cells. [63-65] This regulation of gen e 
transcription may result in inhibition of SARS -CoV-2 replication. Furthermore, in asthmatic 
patients , ICS may lower gene expression of ACE2 and TMPRSS2 . The ACE2 receptor is 
expressed on epithelial cells and bind s SARS -CoV-2 for entry and the serine protease TMPRSS2 
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 76 primes the SARS -CoV-2 spike protein for binding . Lowering gene expression of ACE2 and 
TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection .  
Clinical Studies:  
The P RINCIPLE (Platform Randomized trial of Interventions against COVID -19 in Older 
People) trial is a multicenter, open -label, multi -arm, adaptive randomized, platform trial. The 
trial is ongoing and released an interim analysis after the Trial Steering Commit tee advised the 
Trial Management Group that the pre -specified superiority criterion was met on the time to 
recovery in the overall study population and the subgroup of participants with confirmed positive 
SARS -CoV-2 testing. Participants were eligible if a ged >65 years, or >50 years with 
comorbidities and had ongoing symptoms from PCR confirmed or suspected COVID -19 with 
symptoms starting within the past 14 days. Participants were randomized to any open active 
intervention arm including inhaled budesonide a nd usual care. Participants were followed 
through an online, daily symptom diary for 28 days. Participants received usual care plus inhaled 
budesonide 800 ¬µg daily for 14 days or usual care alone. The primary outcome of the trial at the 
start was hospitali zation or death within 28 days; however, the rate of hospitalization was lower 
than initially expected thus the Trial Management Group and the Trial Steering Committee 
recommended amending the primary outcome to include a measure of illness duration. The t rial 
was completed with two co -primary endpoints measured within 28 days of randomization: 1) 
time to first reported recovery defined as the first day that a participant reported feeling 
recovered; and 2) hospitalization or death related to COVID -19.  
The interim analysis included eligible SARS -CoV-2 positive participants who were randomized 
to inhaled budesonide (N=751) or usual care alone (N=1028). The mean age was 62.8 years and 
83% of participants had co -morbidities. The median days from symptom onset t o enrollment was 
6 days. There was evidence of a benefit in time -to-first-recovery in the budesonide arm with an 
estimated median benefit of 3 days. The point estimate of the proportion of COVID -19 related 
hospitalizations or deaths was lower in the budeso nide group (8.5%) versus usual care (10.3%), 
but this did not meet statistical significance (95% BCI -0.7 ‚Äì 4.8%). There were two SAE s for 
hospitalization unrelated to COVID -19, both in the budesonide group.  
A smaller trial of 146 nonhospitalized adults w ith mild COVID -19 reported that inhaled 
budesonide at the same dose reduced COVID -19 related emergency assessments and 
hospitalization.  
The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The 
equivalent high dose of fluticasone furoate  is 200 ¬µg/day. Inhaled fluticasone furoate has a 
greater anti -inflammatory potency per microgram than budesonide, thus fluticasone furoate is 
administered at a lower daily dose and used only once daily to achieve a similar high dose.  
18.4. Placebo Information  
18.4.1.  Formulation, Appearance, Packaging, and Labeling  
The placebo will be an fluticasone furoate -matched placebo containing lactose for inhalation in 
the same two tone grey inhaler  that is used for the study  drug. The appearance and packaging 
will match that of the study drug (as described in Section 18.3.1 ). All packaging will be labeled 
to indicate that the product is for in vestigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v3.0] 
 
 77 18.4.2.  Drug Dispensing, Storage, and Stability  
Placebo will be stored in the same conditions as study drug, ro om temperature (20¬∞C to 25¬∞C) 
with excursions permitted from 15¬∞C to 30¬∞C in a dry environment away from direct heat or 
sunlight.  The placebo has a shelf life of up to 36 months when stored at ‚â§ 30 ¬∞C. 
18.4.3.  Dosing and Administration  
Participants will self -administer one blister of placebo via inhalation from the inhaler once daily 
for 14 days.  
18.5. Events of Special Interest  
None  
18.6. Safety Reporting for Fluticasone Furoate  
Sponsor will promptly notify G laxoSmithKline of all SAEs, UADEs , and pregnancies (if 
applicable), and medical device deficiencies that have occurred for participants enrolled in this 
Study Drug Appendix, in accordan ce with the timelines and procedures specified in the 
Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow -up 
information as available, to GSK upon request.  
 
 
 